Podcasts about AstraZeneca

In this episode of the Accenture AI Leaders Podcast, Teresa Tung, Global Advanced Data Lead at Accenture, is joined by Russell Smith, VP of ERP Transformation Technology at AstraZeneca, and Nick Tate, Managing Director and Talent & Workforce Lead UKI at Accenture, to discuss how organizations can move from AI experimentation to real business value. Explore why scaling AI depends on people, culture, and adoption not just technology and learn practical insights on leadership and workforce readiness.

Subscribe to our Newsletter:https://theultimatepartner.com/ebook-subscribe/ Check Out UPX:https://theultimatepartner.com/experience/ https://youtu.be/j0TuosYDQe4?si=7mzUwBe4PrQ-eB2E In this insightful session from the Ultimate Partner Live event in Bellevue, Washington, Vince Menzione sits down with Stephen Boyle, Corporate Vice President for Enterprise Partners at Microsoft, to pull back the curtain on the tectonic shifts redefining the tech ecosystem. Boyle details Microsoft's massive organizational pivot into enterprise and SME/channel divisions , explaining how artificial intelligence acts as the foundational thread unifying systems integrators, software vendors, and digital natives. Moving past market noise surrounding competing foundational models , he highlights Microsoft's strategy to become the ultimate “platform of platforms” by prioritizing user choice, security, and trust. Emphasizing a shift away from infrastructure technicalities and toward practical business outcomes , Boyle delivers an urgent mandate for partners to scale technical talent, eliminate traditional operational silos, and brace for the incoming consumption-driven, agent-based future of enterprise computing. Key Takeaways Microsoft has restructured its global sales divisions into distinct Enterprise and SME/Channel organizations to better target its massive total addressable markets. Artificial intelligence is fundamentally altering the partner ecosystem by dismantling traditional software and systems integrator silos to build interconnected, multi-party solutions. Rather than forcing alignment to a singular model, Microsoft aims to be the definitive platform of platforms by offering extensive choice across over 1,100 language models. The enterprise landscape is rapidly moving past experimental AI pilot phases and entering production setups completely focused on transforming core business outcomes. Tomorrow's service organizations are aggressively evolving into software-minded operations that deploy repeatable, highly specialized internal autonomous agents. Managing tokens and monitoring usage metrics represents the emerging operational baseline for balancing efficiency against the scaling expenses of large language models. If you're ready to lead through change, elevate your business, and achieve extraordinary outcomes through the power of partnership—this is your community. At Ultimate Partner® we want leaders like you to join us in the Ultimate Partner Experience – where transformation begins. Key Tags AI frontier, platform of platforms, enterprise partners, global systems integrators, digital natives, language models, token consumption, agent sprawl, citizen developers, shadow IT, business outcomes, technical enablement, marketplace growth, hyper-scalers, processing fluency, sovereign AI, industry ecosystems, data governance. Transcript [00:00:00] Stephen Boyle: This is the biggest, most transformative, iterative change in technology we’ve ever seen, where, if you wanna call it a paradigm shift or whatever word comes after paradigm shift. [00:00:12] Vince Menzione: We just came back from Ultimate Partner live in Bellevue, Washington, where we hosted incredible leaders for two amazing days. Come join us for this next session where we explore the tectonic shifts we’ve all been seeing. Uh, I am thrilled to invite our next guest up on stage. I’ve known this gentleman for several years back in my days at Microsoft, and, um, we’ve been friends, actually Microsoft, and then we both went and did different things, came he’s come back to Microsoft in a big way. [00:00:46] Vince Menzione: Uh, Steven Boyle, for those of you don’t know, is recently a named the C. We will talk about it in a second, but I, I need to announce you properly. Is the corporate vice president, which by the way in Microsoft is a big deal for enterprise partners. He and Nicole De and I would say are the two Microsoft leaders in the organization. [00:01:06] Vince Menzione: Nicole is the channel chief. Steven has a, a big remit and we’ll talk about that up on stage. But I’m just so delightful for his support and for making the time in a very busy week at Microsoft ’cause this is CEO summit this week to make some time to come with us and be on stage with me. Please welcome my good friend Steven Boyle. [00:01:29] Vince Menzione: Good to see you, sir. To see. So I’m gonna put you on this side. [00:01:33] Stephen Boyle: Okay. [00:01:35] Vince Menzione: The hot seat. So I’m gonna, I, I didn’t do a justice and I, I wanted you to explain your role. I, I think I know, but I think for the, for the people in the room, uh, talk to us what Enterprise Partners means at Microsoft and what that role remit and remit looks like. [00:01:50] Stephen Boyle: Um, CVPs may or may not be important, but one thing they don’t do is get invites to the CEO summit. So I’m super pleased to be here with you guys. No, no, it’s totally cool. It’s totally cool if that phone rings. No, I’m kidding. Doesn’t. So what does it mean? So I’d like quickly, um. January last year, uh, we split the sales organization into enterprise and small to medium enterprise and channel. [00:02:15] Stephen Boyle: You guys probably familiar with that? Nicole is the, uh, chief partner officer lives in the SMA and C world and drives the channel, um, drives our marketplace business and, and a lot of other things. Um, for that 60 billion, um, you know, total addressable market that we have. Down there in SME and C. Um, at the same time, we established enterprise partner as part of Nick Parker’s overall organization. [00:02:40] Stephen Boyle: Um, but for most of 2025 we ran it as global systems integrators and advisories, ISVs and digital natives. So three separate footprints all focused entirely on, on, on enterprise. Um, in December, January, we talked about establishing an enterprise partner leader that would. You know, aggregate all of this stuff. [00:03:00] Stephen Boyle: Um, I was fortunate to come through, um, some frankly, pretty hairy, uh, experiences, I bet with some of our senior leaders. Um, I, I’ve loved to [00:03:08] Vince Menzione: been in the room for that [00:03:09] Stephen Boyle: questions like, why Steven Boyle and things like that, right? And really have to dig deep to, uh, to justify. Anyway, uh, I’m blessed and honored, uh, to run that entire portfolio of partners, uh, for the entirety of the enterprise partner world, which now from a chief revenue officer perspective, belongs to Deb. [00:03:25] Stephen Boyle: Deb Co. So Deb is the enterprise leader for all of our sales that we do into that space. Awesome. Um, I have three regional leaders, Nina Harding here in the United States, Ehab Ra in in Europe, and Heather Gordon in Asia that mirror and replicate and flow down the things that we decide to do from a strategy perspective for the, uh, for the core. [00:03:45] Vince Menzione: And we love Nina. She’s been, she was at our last event, [00:03:47] Stephen Boyle: super, super lady. And, uh, you know, the US is still 50% of our overall business. [00:03:53] Vince Menzione: Yeah. [00:03:53] Stephen Boyle: Too big to fabric. Every time I talk to Nina, I’m like, Nina, you’re too big to fail. We can’t cover you anywhere else. So you know, you’ve gotta be successful here in the Americas. [00:04:01] Vince Menzione: So I think just for breaking it up, I, ’cause I do want to like, it’ll lead to the next question, right? So you have the global systems integrators, all these systems integrators. Essentially you have all of the software companies we used to call ISVs, we now call SDCs or software development corporations. [00:04:17] Vince Menzione: And then you also have the AI stack, I’ll call it. Right? So under Jason Grafe. Yeah. Many, many might know. Jason’s been a guest on the podcast and was Satya’s chief of staff at one time, eight years. Eight years. Wow. I didn’t realize there was that many. [00:04:31] Stephen Boyle: Carry carried a lot of bags for Satya over the years. [00:04:34] Vince Menzione: Unbelievable. Well, let’s, I mean, so AI is an important component, right? And you saw Jay’s, Jay talking, just talking about AI and all these things. I would love to start here, right? Because, uh, you’re, you’re, I wanna get your perspective as Microsoft, your perspective as Microsoft on the biggest shifts you’re seeing in defining this we’ll call AI Frontier. [00:04:54] Vince Menzione: We’re seeing right now, how should partners translate that into how they position and go to market externally? How, how do we need to think about this time? [00:05:02] Stephen Boyle: Yeah, that is, uh, that is a huge question and I’m not sure we’ve got enough time to go into the, into all of the detail. Um, so let me sort of up level it a little bit for you. [00:05:10] Stephen Boyle: And I think, look, the move that we meet at made a couple of months ago and pulling together those three aspects. Nicole had already done it in SME and C. Right. One partner organization across the world with a very common set of goals. We were working closely together, Sandy Gupta, on ISV, Jason on ai, and myself on on si. [00:05:29] Stephen Boyle: But we were still working closely together across silos. So the opportunity for me, 60 days into this role is AI just allows you to wire the partner ecosystem together differently. Right? And even if you look at how we’re going to market an AI today, um. You know, with, with, with chat GPT, with Claude, with Anthropic, um, I think there’s something like 1100 different, you know, language models on Microsoft today. [00:05:55] Stephen Boyle: So the way I think about AI is we are absolutely gonna be the ultimate platform of platforms. Yeah, choice is incredibly important. Um. It’s, it’s, you know, turn the clock back 12 months, everybody was chat gpt five point x, you know, and then six months ago it was Gemini and now it seems to be clawed. And honestly I don’t know what it’s gonna be next quarter. [00:06:15] Stephen Boyle: So the only thing I can do is offer you choice. [00:06:18] Vince Menzione: Yeah. [00:06:18] Stephen Boyle: And from a partner perspective, I think that minimizes or reduces the risk that you have betting on the Microsoft platform because you can go in a multitude of different directions. I know we’re not in Europe, but if you were in Europe and you were worried about G-G-D-P-R and Jay mentioned sovereignty, you’d probably be like lining up really closely to Misra. [00:06:37] Stephen Boyle: Yeah. And a bunch of other Europe, European partners. So wherever you are in the globe, I wanna be that platform choice. Um, and we will lead with our own first party solutions. I hope they’re not coming for me. Um. I parked safely in the hotel. It can’t be me. Um, but you weren’t vibe coding in the room. Um, but you know, wherever you are in the world, in whichever industry you are in, um, it is our intent to, to offer that platform of platforms and to give the broadest set of partners the opportunity to engage with us. [00:07:07] Vince Menzione: I think that’s really important because I, I have found, especially in the last month or two, people are, it’s almost like a knee jerk. Don’t you feel like people don’t know what to do? There’s been so much noise in the press and the media and, and the markets around open AI and anthropic especially. Where do I go? [00:07:26] Vince Menzione: Seems to be like when I, when I sit, I watch everybody in the room here. I think they’re, they’ve all been thinking that as well. So you can, [00:07:31] Stephen Boyle: there’s a, a little bit of a deer in the headlights moment. Yes. And even I like, I get that. Yeah. Um, you know, I saw, uh, Jay slides. Jay, love the presentation. Love the slides, man. [00:07:40] Stephen Boyle: I’m gonna steal several of them. Um, we’ll talk about that later. We, we [00:07:43] Vince Menzione: have the deck, [00:07:45] Stephen Boyle: but, but in all seriousness, you know, this, this is like. It’s a new paradigm. I will date myself a little bit. Some of you might heard me say this. I sold many computers in the 1980s. Mini computers. Some of you in the room are going, what’s a mini computer? [00:07:59] Stephen Boyle: Um, I sold client server for Sun Microsystems in the nineties. I sold an awful lot of Oracle databases in the Auts, I think they’re called, and I’ve done two stints with Microsoft. This is the biggest, most transformative. Iterative change in technology we’ve ever seen. What, if you wanna call it a paradigm shift or whatever word comes after paradigm shift. [00:08:18] Stephen Boyle: Um, and we are building intelligent systems at scale faster than we’ve ever seen. Scalable, mission critical solutions being implemented today inside of Microsoft and with our most important customers. So, and we can’t do it without partners, right? There is absolutely nothing we can do in this industry. I will, I will put the, you know, the elephant in the room out there. [00:08:40] Stephen Boyle: Our ISD organization has between five and 7,000 people. Our forward deployed engineering organization is about a thousand people. [00:08:47] Vince Menzione: Yeah. [00:08:48] Stephen Boyle: So when you look at the scale of the total addressable market that Jay just talked about. We are gonna service directly like this much [00:08:55] Vince Menzione: used to be 5%. Was it even, is it even that high? [00:08:58] Stephen Boyle: I doubt it’s, I doubt it’s even that. And the billions of dollars that we spend every year helping our customers transform to what we’re now calling frontier firms is gonna be, have to be driven with every single person in this room in some way, shape, or form. Judson is not asking Marla to significantly increase ISD. [00:09:15] Stephen Boyle: Not asking John to significantly increase FDE, although we probably will hire in that area just because of the, the newness and the, you know, bright shiny object that everybody’s like, oh, FDE, I’ve gotta have those. We’ve got a thousand already today that have been around in John’s organization for 10 plus years doing the things that we are doing today. [00:09:32] Stephen Boyle: But we are gonna build out that muscle. But the real way we’re gonna build out that muscle is with all of you in this room. That’s like categorical. That is my like, probably number one goal for the next one to three years is make sure that, that story that Jay just told about Microsoft not being involved in AstraZeneca. [00:09:48] Stephen Boyle: I probably won’t tell Judson that Jay, but I love the story. Um, like if you could all do that for me, like win, um, that is so, you know, from our worldwide learning, through our skilling enablement through our cloud solution architects that I personally own. We are pivoting aggressively towards making sure that the partners understand our platforms better than any other job, number one for me right now, if you don’t understand what I’m selling, like I’m kind of dead in the water obviously. [00:10:15] Stephen Boyle: Well, [00:10:15] Vince Menzione: I was gonna ask you why now? Why Microsoft? Why now? Right? Because there is a lot of noise. You know, Google just announced, you all announced your results on the same day, which was astounding. That was freaky, wasn’t it? It was. It was the first time. And the, the total commitment, customer commitment is over a trillion dollars now, I think 1.2 trillion is what I counted up. [00:10:33] Stephen Boyle: Yeah. [00:10:34] Vince Menzione: But it’s saying a lot about like, what do I do now, like as these partners in the room. Um, how, I think you kind of already, and you’ve talked about this, about differentiating where Microsoft is, I think J Slide does a lot of justice there. It says how, uh, Microsoft Partners came into the room, surrounded the customer. [00:10:52] Vince Menzione: It feels like Microsoft has always leaned in big time on partners. Uh, more so I would say than any other organization out there. What would [00:10:59] Stephen Boyle: you say Joe Roses, my chief of staff, business manager and so many other things was telling me last night that, you know, we used to say 500,000 partners. [00:11:05] Vince Menzione: Yeah, [00:11:06] Stephen Boyle: it’s a, it’s a significantly higher number than that as well. [00:11:09] Stephen Boyle: So there’s an element of, you know, back to the deer in the headlights, which partners are, are more important. One of my other phrases that I say on a regular basis, the winners and losers are yet to be decided in this next wave. Like, I want all of us to on the right side of that argument. Right? But, but it’s gonna be a challenge and, and companies are going through shifts. [00:11:28] Stephen Boyle: You know, Accenture, maybe, possibly doesn’t need 750,000 employees in the not too distant future. Maybe TCS at 600,000 doesn’t need 600,000 human employees. So we’re going through this dramatic shift of, you know, what’s the right balance going forward. What I would say about Microsoft is notwithstanding the fact that we’ve figured this out for 51 years, which is a little bit mind blowing, um, that you know, all the way back in the seventies we’ve gone through so many iterative changes. [00:11:56] Stephen Boyle: People have questioned just like they’ve questions. A lot of other technology companies, are you gonna be around for the long haul? I think we’ve proven time and time again, and I love Jay’s story. I’ve used that myself about how many companies disappear on a, on a decade to decade, you know, business. 10 years ago I had the opportunity to listen to Craig Clayton Christensen, who’s sadly no longer with us. [00:12:15] Stephen Boyle: Yeah. But you know, the books that he wrote and the story that he told to Microsoft 2014, we were nowhere in cloud. [00:12:21] Vince Menzione: Yeah. [00:12:22] Stephen Boyle: AWS was so far ahead of us, it was crazy. And he came in and he’s like. You know what? You guys need to be successful. You need to figure out how to cross this chasm again, and we’ve done it time and time again. [00:12:32] Stephen Boyle: You can go back. You know, Microsoft used to be known as a fast follower in ai. I don’t think we’re a fast follower. I think we’re right up there. We’re right at the front, but that race is still being run and the winners are losers are yet to be decided. [00:12:44] Vince Menzione: I was in that room with Clayton Christensen with you, by the way. [00:12:46] Vince Menzione: I remember, I remember that. That was at a Prism conference. [00:12:49] Stephen Boyle: Yeah. Yeah. [00:12:50] Vince Menzione: You men, you touched on this with the GSIs a little bit. How do you see the roles evolving? You know, we, we, we bucketed all, we’ve always been. Fantastic about bucketing ISVs or SDCs and sis and digital natives. Yeah. How does it, how does that all come together? [00:13:06] Vince Menzione: Does it come together any differently in this new AI platform era, or is it the same? [00:13:11] Stephen Boyle: I look, I, I’ve said this for a long time, like if you go into AstraZeneca, the six plus, you know, frontline partners, there’s probably a whole board of second, third tier that, that we don’t know about doing, you know, things across the AstraZeneca group. [00:13:25] Stephen Boyle: It takes several villages and sometimes a small town, especially in my world, in the enterprise world, strategic five hundreds. Yeah. Um, you know, we, we ran some reports a few years ago and it is shocking how many global systems integrators have a footprint in Shell or Exxon or, you know, bank of America or whatever else. [00:13:44] Stephen Boyle: So I’ve always believed that partner to partner is critical. Yeah. I think it became even more critical in the, in the AI world, and I’ll take my new friends at Anthropic. So I went to the first Anthropic partner Summit. Some of you might have been down there in, in San Diego, um, just a couple of months ago. [00:13:59] Stephen Boyle: Same partners, same people from the same partners. In the room, you know, talking about what they’re gonna do together with Anthropic. Um, and I’m looking out across this audience going, okay, well I know him and I know her and I know those guys, and like, I need to figure out how I’m gonna weave this together. [00:14:14] Stephen Boyle: So it’s not just an Accenture and Anthropic or an NTT data and anthropic, but it’s an NTT data plus anthropic plus Microsoft. Story going forward. And then who’s best at delivering those services capabilities? So it’s it at every juncture that I see in the, in the partner community, and this is the, the reason why I argued vehemently with Nick, that it has to be one organization I’m gonna create maybe given a little bit away. [00:14:40] Stephen Boyle: So if you’re recording, stop now. Um, I’m gonna create an enablement organization that is partner agnostic. I don’t necessarily care. I do care about the digital natives, but I don’t care about how I train them. Right. What I’m more important of is how do I train the digital natives in what the sis are doing, and how do I train the sis and what the ISVs Plus digital Natives are doing. [00:15:01] Vince Menzione: Yeah. [00:15:01] Stephen Boyle: That is my, that’s my game plan. If I fail there, then I think we fail to raise the bar and be differentiated in an AI world, and I’m not set up like that today. [00:15:12] Vince Menzione: I wanna, I wanna ask you, uh, uh, because I was looking at Jay’s slide and the, the managed piece is. And we have a lot of managed service providers in this room today. [00:15:20] Vince Menzione: A lot of them, by the way, come from the old school of managed services. The managed piece seems to be like, if I’m doing something today with ai, we’re gonna talk about security next, uh, up on stage here. It seems like there’s a new set of skills or a different approach to the customer, don’t you? Don’t you agree? [00:15:37] Stephen Boyle: I I [00:15:37] Vince Menzione: think you need to keep your hands on the steering wheel at all [00:15:39] Stephen Boyle: times. I think what it boils down to is you can’t do AI unless you do certain other things. [00:15:44] Vince Menzione: Yeah. [00:15:44] Stephen Boyle: Right. You could be a modern work specialist and you could make a lot of money being a modern work specialist, or you could be a, a dynamic specialist. [00:15:52] Stephen Boyle: We just held our, uh, inner A in a circle conference last last week, which I was disappointed to miss for the first time in a few years. Those, those days are, are, are fast becoming over. [00:16:03] Vince Menzione: Yeah. [00:16:04] Stephen Boyle: Um, why? Because everything that I’ve just said is tied together by ai. Yes. And in order to do good ai, you need good data. [00:16:12] Stephen Boyle: And in order to trust everything that you’re getting, as Judson talks about trust and intelligence, you need to wrap that in a really secure [00:16:19] Vince Menzione: Yes. [00:16:19] Stephen Boyle: You know, en en environment. Now we will do our best to provide levels of security into how we deliver ai. But that’s not the end of the game, right? You have to take it all, all the way to the edge. [00:16:30] Stephen Boyle: So that’s why a siloed partner or a singular commercial solution area partner in Microsoft’s terms, has got to transform its business. ’cause if you’re gonna do ai, you’ve gotta do those other things as well. [00:16:41] Vince Menzione: Agreed. I must see the model changing, and in fact, I see like bigger organizations becoming managed service providers in many respects. [00:16:48] Stephen Boyle: Yeah. Yeah. I mean, look, there’s still, there’s still a role for all the old terminology you mentioned is SV to sdc. Yeah. I’m like, I’m been around long enough. Look, it’s ANB still anv, it’s still an isv. Thank you. Independent software vendor. Um, and it’s, you know, where, where AI is allowing software to be, you know, frankly developed in a number of different places. [00:17:07] Stephen Boyle: We are all citizen developers. Um, you know, I was on a call with our internal leadership yesterday, um, and you guys might have heard this story ’cause I think it came out at Ignite. When we turn the agent 365, around and on ourselves. We found 130,000 agents running across Microsoft that had been developed and deployed internally with, I mean, you could call it shadow it. [00:17:28] Stephen Boyle: I guess that would be one phrase that you would use for it, but the reality is if you, if you haven’t got something to do your job today, you have the tools. To build it really, really fast. Um, and that, you know, that’s, that’s a great opportunity for people to be able to do their work, you know, in a better and in a different way. [00:17:45] Stephen Boyle: But it’s also a huge opportunity to make sure that data governance and security and all the other things that we need to deliver are there out of, out of the gate and out of the platform that we deliver. So security’s absolutely critical. Not saying that managed services won’t grow, um, at, at some level as well, but only if they transform into this multifaceted way. [00:18:04] Stephen Boyle: Yeah. Thinking [00:18:05] Vince Menzione: about, well, that’s what I was, I was gonna lead to here with innovating. It’s happening across, I mean, we’re talking about chips, we’re talking about foundational models, LLMs, we’re talking about applications, we’re talking about agents. How should we think about where to play and how to differentiate as partners in this room? [00:18:22] Stephen Boyle: I think. [00:18:25] Stephen Boyle: So look, I mean, one, one of the ways that Judson talks about it is I think silicon’s gonna change over time. Yes. NVIDIA’s definitely the 800 pound gorilla, maybe the 8,000 pound gorilla. Yeah. Uh, but you know, if you read the press, there’s, there’s things happening in, in different places as first party silicon, which we clearly are, are developing, um, in a quantum direction for sure. [00:18:45] Stephen Boyle: Um, there’s lots of different language models that haven’t even been launched on, on, on the marketplace yet, so. You know, Judson’s trying to uplevel our conversations. You’ll hear us talking about conversations more and more as we go into FY 27, um, that obviate all of those layers. Just like even when I was selling Sun Microsystems, it was about the business outcome and the business solution that we were solving for not necessarily the fastest piece of hardware or the best client service solution on, on the market. [00:19:17] Stephen Boyle: So I think what’s gonna happen over the next 12 to 24 months is we’ll have so many different models to choose from. We’ll have more silicon to choose from, but those won’t be the real buying decisions. The real buying decisions of what? How am I trying to transform my finance organization, my HR organization, and my supply chain? [00:19:36] Stephen Boyle: Because the underlying technology, Judson says commodity I, I guess I can go with that. It will be commoditized and we’ll really start to focus back on what the important things are. We’re moving a lot from pilot to production. You guys have probably seen that. The numbers that Jay just showed about how many. [00:19:52] Stephen Boyle: Projects are failing, is getting less and less because we’re getting smarter and smarter about what it takes to actually drive the business outcome. And I need all of us to be talking that same language. Yeah. Having conversations with head of HR about how we’re gonna transform human capital management in the, in the age of agents, if you like, like the underlying platform. [00:20:14] Stephen Boyle: It’s not, don’t worry about it. You wanna be on a secure platform. Don’t get me wrong. But at the same time, I don’t think we, we spent too much time worrying about that. [00:20:21] Vince Menzione: Yeah. We’re not, what you’re saying is we’re not spending enough time on outcomes. On the business outcomes. Right. And that’s where we need to focus. [00:20:27] Vince Menzione: We’re, we’re focusing on, I, I feel like we’re, it’s a signal to, to noise ratio that we’re living through right now. There’s too much noise. [00:20:33] Stephen Boyle: Yeah. [00:20:34] Vince Menzione: And we’re not focusing on the signal. I think that’s what you’re saying. [00:20:36] Stephen Boyle: I, it’s got to be, I mean, to be honest with you, it’s always been, you know, even when I sold what I would perceive, you know, sun in the nineties was a rockman ship to the stars and, you know, kind of sad what happened to that company. [00:20:47] Stephen Boyle: Um, but we, we were, we were fixated on, we had the best client server. But, but nobody was buying, you know, a piece of Sun hardware as a room heater, which is all it did, you know, like for the longest. But if you had SAP, if you had Cybase, if you had Bond, remember Bond, I mean all of those applications that drove the business outcomes, we’ve gotta get back to that kind of mentality. [00:21:09] Stephen Boyle: Yes. And worrying a little bit less about the underlying architecture. Yeah. It needs to be, it needs to be part of the conversation. ’cause it needs to deliver trust and security and intelligence and everything else. Then you need to rapidly move to what are you trying to achieve and how can we ensure the, the, the success of, of your business outcome. [00:21:27] Stephen Boyle: And look, I mean, Palantir pri you know, sort of came out and said, well, the way we do that is through forward deployed engineering. Um, and they stole the show. And, and, you know, they’re, they’re doing very well as a result of doing that. Uh, but if you go and talk to, um, Tom Siebel’s organization at C3 ai. [00:21:43] Stephen Boyle: They’ve had FDS for quite a while. You know, I told you about John Chuchu 10 years ago. John Chu, Chuck’s job was to go and get all the applications that we needed on the Microsoft phone. Remember that? [00:21:54] Vince Menzione: Yes. Um, [00:21:55] Stephen Boyle: you know, so we’ve pivoted John o over the years to doing what he’s doing now, which is to go sometimes in partnership with, with partners into the customer and say, what is it you’re trying to achieve? [00:22:05] Stephen Boyle: Let me show you how I can build that for you in three weeks or three months. That might have taken you three years. We literally just did a hackathon with one partner last, last, last week with, uh, with our ISE organization, the, the, the forward deployed, uh, group that John runs. Um, and one of the big customers said, I’ve just done in three days what would’ve taken me three months. [00:22:26] Stephen Boyle: Now he hasn’t productized it and rolled it out and blah, blah, blah. But the reality is that is how fast things are changing. And this was not a small company. This was a very, very large oil company, and they were like blown away by how much we can achieve. We’ve gotta do that at scale. [00:22:41] Vince Menzione: Yeah. [00:22:42] Stephen Boyle: You know, we, we have a commitment to scale our FDE community through partnerships to touch all of the S 500 in a very personalized way. [00:22:51] Stephen Boyle: And then, you know, at a slightly, you know, lower ratios down through the, through the majors and into, into Nicole’s SME and C world as well. [00:22:59] Vince Menzione: Jay talks about the decade of the ecosystem. He coined that term back, back on a podcast way back in nine, in, uh, in 2020. Microsoft has been at the, for, we used to call partner to partner back, back in the day. [00:23:10] Vince Menzione: Mm-hmm. Do you remember those days? How do you think about this ecosystem evolving and what steps are you taking to help bring these organizations together? Because I, I, again, we look at the seven seats or 6.3 seats at the table. The customer has the power now that they didn’t have before. ’cause they have the commitment with like with Microsoft and they can buy off of the marketplace and pull together multiple organizations to go, go do that. [00:23:34] Vince Menzione: How do you think about helping to orchestrate that as the leader of the enterprise partner business? [00:23:39] Stephen Boyle: So I’ll start with a really big example, and I’ll try and sort of scale it down a little bit. But my friends at Accenture, with the Accenture, Microsoft Business Group, we spend an awful lot of time, you know, in, in each other’s pockets, in each other’s deals. [00:23:51] Stephen Boyle: We know everything that’s going on in the Accenture, Microsoft Business Group. And a couple of weeks, or maybe a month or so ago, I was told that the Microsoft Business Group is now larger than the SAP Business group. It probably flip flops. [00:24:03] Vince Menzione: Yeah, [00:24:04] Stephen Boyle: it won’t be too long before the Anthropic Business Group is bigger than both of those. [00:24:08] Stephen Boyle: So what I need my Microsoft team to do is to not spend all of their lives in the. A MBG, the Azure, the Accenture, Microsoft Business group, but to go make friends in the Anthropic Accenture Business group and frankly still to make friends in the SAP business group and maybe in the Oracle Business Group and the list goes on. [00:24:27] Stephen Boyle: So at a macro 11, in the very largest accounts where we haven multiple practices, where we haven’t spent time before, I’m gonna. Push my people into uncomfortable zones and I’m gonna push them to go into those other areas and I’m gonna load them up with technical talent and cloud solution architects and ai, you know, forward deployed engineers. [00:24:45] Stephen Boyle: And I’m gonna force different people to talk together that haven’t talked together. So I can do that in TCS. I can do that, Capgemini, I can do that. Um, you know, in Europe with Capgemini and Misra is a classic example. Um, with the, with the Indian sis, Indian based sis, they’re all big enough where I know all the practices exist. [00:25:04] Stephen Boyle: I just need to do a better job of, of talking to them. Now, when you downsize that into, you know, into a, a company that doesn’t have all of that scale, this the same truth still holds. I need to talk to people who aren’t necessarily motivated every single day to do something with Microsoft. I need to talk to people who are motivated to do something with an AI partner or even a traditional SaaS partner. [00:25:27] Stephen Boyle: I noticed yesterday, actually no, this morning I got a notification that we just passed, um, a billion dollars in revenue on the marketplace with ServiceNow. [00:25:35] Vince Menzione: Nice. [00:25:36] Stephen Boyle: Um, and I think AWS announced the same thing, by the way this month as well. Um, so thank you to the ServiceNow people. Yeah. Um, you know, that is that there’s a tremendous demonstration of how far we’ve come in marketplace. [00:25:48] Stephen Boyle: ’cause that’s another one where we trailed AWS quite significantly. But with the right partnerships. And driving the right motions, we can, you know, we can definitely catch up and we will continue to pass, uh, some of, some of the other hyperscalers in, in, in that way. So really the bottom line to your question is partner to partner is still real. [00:26:08] Vince Menzione: Yeah, [00:26:08] Stephen Boyle: how we do it and what we use to tie things together. And I know that compensation drives behavior and we’re not gonna get into a compensation about like how we get compensated and everything else, but the reality is I’ve gotta break down those barriers and those silos and I’ve gotta deliver real meaningful enablement and practice development so that, so that the people who sit in the Anthropic business group and the people who sit in the Microsoft Business Group are spending as much time together as they are with me. [00:26:34] Stephen Boyle: That makes sense. Simply put, that’s what I, I need to achieve at scale rapidly. [00:26:40] Vince Menzione: So to, we’re getting close to time here, but as you look forward, what would define the most successful partnerships in this ecosystem? Is it, is it what you described, the opening up the aperture or for the, for the leaders in the room here today, what should they go do better and differently? [00:26:58] Stephen Boyle: Um, so obviously we’re closing out this fiscal, we’ve got Microsoft start and Microsoft start for partners coming up in July. Um, I mentioned the fact that we’re, we’re driving. Cu customer engagement through the lens of conversations and how do we achieve business outcomes? I would encourage you to, to gravitate, if you like, above the commercial solution areas where you might have understood, this is how I interact with Microsoft today. [00:27:23] Stephen Boyle: Um, and abstract it up to that AI layer. You know, think about trust, think about intelligence, think about business outcomes, and how do I potentially weave together a story? If I’m in the dynamic space, how do I get better in data? If I’m in the data space, how do I get better in. In that modern work environment, but really use AI as the overlay to, to help tie that together. [00:27:44] Stephen Boyle: That’s one thing. The second thing is if we’re not training you in the right direction, it’s stevenBoyle@microsoft.com. Let me know. Awesome. Um, we’ve got programmatic stuff, um, you know, and we’ve got high touch stuff as well. So I think this is, this is another time where Microsoft is gonna over pivot on all of the training and enablement that we need to do to make sure that you’re, you know, you’re grounded in our platform. [00:28:07] Stephen Boyle: Um, I think there’s a huge opportunity with this agenda future to become more of a software partner. You know, even the deepest services organizations are going to need agents, and the more successful ones will be the ones that can turn on those agents in a repeatable way. So. Our agents, the new SaaS. I’m not exactly saying that, but I think that the agen future is one where even the more services oriented companies will, will have teams of agents that they’re deploying. [00:28:35] Stephen Boyle: In fact, I had a very, very large systems integrator, um, in, in the EBC just about a month ago, three weeks ago. Um, and I was sat next to their head of consulting and he showed me what he called his God dashboard. Uh, and right in the middle of his God dashboard there are like 450 accounts. All of whom I recognized, ’cause they were all in the enterprise, right in the middle of his dashboard was, how many tokens am I spending? [00:29:00] Vince Menzione: Yeah. [00:29:01] Stephen Boyle: Like, not like what’s my daily runway? You know, not am I making a profit on that account or anything else like that is like, how many tokens have I consumed? Yeah. Because there is an awful lot of, that is the new juice, if you like. That’s, that’s driving the success. You can have the smartest people on the planet, but you’ve got to still arm them with all the best tools that are available out there. [00:29:22] Stephen Boyle: So it’s fascinating to listen to him, how he had gone through that thing of, you know, agent sprawl, how many are really working, how many are not working? How can we prove that? You can prove it through, you know, managing your tokens. There’s a new version of. Finops for tokens, for want of a better phrase, that’s gonna be critical for us all to understand. [00:29:40] Stephen Boyle: ’cause they’re not cheap, they’re not free, that’s for sure. And, and they might not be cheap if you’re not, if you’re not managing them and using them effectively. Yeah. So that’s the other thing that I would really get on top of. And, you know, we’re gonna make some announcements in the not too distant future about the consumption driven future. [00:29:56] Stephen Boyle: Um, that, that we will, that we will deliver with our first party and third party platforms going forward. So that’s another. Another critical thing [00:30:03] Vince Menzione: sounds like some exciting announcements. Pretty soon. [00:30:06] Stephen Boyle: Yeah, could look close. Quarter four, help me close. Quarter four. Yes. That’s priority number one, two, and three right now. [00:30:12] Stephen Boyle: Uh, but get ready for some, you know, for some new announcements in July. Um, look, the future is incredibly bright with Microsoft. It’s incredibly bright in the industry as a whole, right? I mean, let, let’s be honest, the, the growth targets that we will have for ne next year are astronomical, and we will not make them without the partner community that we have, without training and enabling the partner community that we need for tomorrow. [00:30:34] Stephen Boyle: So like, stay close, you know, stay engaged. Talk to your partner development managers, talk to the talk to field reps, talk to the accounts that that, that you are in, and stay as close as you possibly can to our emerging strategy. And, um, you know, look, I, I think if I had fivefold or tenfold the people I have today, I still wouldn’t be able to touch everybody that I would like to touch in the partner community. [00:30:58] Stephen Boyle: So I’ll apologize in advance. Um, but we’re gonna have some, you know, some really cool ways of learning. Um, and we’re gonna make sure that they’re available to the widest possible audience. [00:31:07] Vince Menzione: Well, we bring the practitioners and the experts in the room to help with that as well. Right? Yeah. Because you can’t always have a partner development manager tied to everybody in the room. [00:31:14] Stephen Boyle: I, I would do hackathons on AI every week with every partner and every part of the world, but I can’t. [00:31:19] Vince Menzione: Yeah, exactly. Well, so good to have you today. Thank you. So good to see you again. I don’t know what your schedule is like. I, we didn’t, we don’t have enough time for questions. [00:31:28] Stephen Boyle: That’s cool. [00:31:28] Vince Menzione: From the audience. [00:31:29] Stephen Boyle: I’m gonna stay around for a little [00:31:30] Vince Menzione: while this [00:31:30] Stephen Boyle: morning and I’m coming back [00:31:31] Vince Menzione: for cocktails. Alright, terrific. So. Stephen Boyle will be here for cocktail hour. Thank you. Four 30 and uh, I wanna thank you, sir. So good to have you. Thank you. Good to see you. Absolutely. [00:31:42] Stephen Boyle: So much. Absolutely. Hey, thanks everybody. [00:31:43] Stephen Boyle: Thanks for what you do today, and hopefully thank you for what you do tomorrow as well. [00:31:46] Vince Menzione: Thank you. An incredible leader. [00:31:49] Stephen Boyle: Don’t forget, ultimate [00:31:51] Vince Menzione: partner Alive is coming soon, June 18th at our executive breakfast in New York. I hope to see you there.Description The Future of Tech is Here. Subscribe to our Newsletter:https://theultimatepartner.com/ebook-subscribe/ Check Out UPX:https://theultimatepartner.com/experience/ I

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a series of remarkable updates that highlight the dynamic evolution of drug development, regulatory landscapes, and industry strategies. Takeda has made waves with its TYK2 inhibitor, Zasocitinib, which recently outperformed Bristol Myers Squibb's Sotyktu in a pivotal Phase 3 trial for plaque psoriasis. This trial is particularly noteworthy as it involves TYK2 inhibitors, a class of drugs targeting tyrosine kinase 2 to modulate immune responses. The success of Zasocitinib not only strengthens Takeda's competitive position but also underscores the potential of these inhibitors in treating autoimmune conditions like psoriasis. As we look forward to its market launch next year, this development represents a significant stride in the realm of targeted therapies aimed at complex diseases. Shifting gears to regulatory advancements, Johnson & Johnson's Darzalex (daratumumab) has received endorsement from NICE for its quadruplet therapy in newly diagnosed transplant-ineligible multiple myeloma cases. This approval is based on favorable Phase 3 trial results and highlights the therapeutic potential of targeting CD38 on myeloma cells. This marks a crucial step in offering potent treatment options to patients who cannot undergo transplants, emphasizing the growing importance of combination therapies in oncology. In another significant development, Johnson & Johnson is expanding its rare disease portfolio with promising Phase 2/3 trial data for Imaavy. Poised to become the first approved treatment for warm autoimmune hemolytic anemia, this advancement highlights the industry's pivot towards addressing rare diseases with limited treatment options. In India, AstraZeneca has secured CDSCO approval for Enhertu (trastuzumab deruxtecan) combined with pertuzumab as a first-line treatment for HER2-positive unresectable or metastatic breast cancer. This approval signifies a milestone in HER2-targeted therapies, spotlighting the pivotal role of antibody-drug conjugates that deliver cytotoxic agents directly to cancer cells, enhancing efficacy while minimizing systemic exposure. Moving on to business developments, Servier's partnership with N-Lorem Foundation to develop antisense oligonucleotide therapies for rare neurological disorders reflects the industry's increasing focus on precision medicine. This collaboration underscores the burgeoning interest in nucleic acid-based therapies aimed at addressing genetic disorders lacking effective treatments. On the financial front, Kardigan's planned $320 million IPO signals robust confidence in advancing cardiovascular pipeline assets. This move highlights Kardigan's commitment to tackling substantial unmet needs in cardiovascular diseases—an area still rife with challenges despite existing therapies. From a regulatory perspective, China's update of its Good Clinical Practice guidelines aims to streamline clinical trial processes, fostering biotech innovation. This change is expected to enhance drug development efficiency and attract global biotech investments to China's rapidly growing pharmaceutical market. Meanwhile, Pfizer CEO Albert Bourla has raised concerns about Germany's healthcare reform plans, warning that they might deter future investments. His comments underscore the delicate balance between cost containment policies and maintaining an environment conducive to pharmaceutical innovation. Additionally, Novo Nordisk's CEO Mike Doustdar expressed optimism about the company's strategic focus on market positioning through innovation and efficiency improvements. This aligns with broader industry trends where large pharma companies strive to maintain leadership roles amid fierce competition. Eli Lilly's sponsorship of short films premiered at Tribeca Festival illustrates an industry-wide trend toward patient-centric approaches and authentic portrayals of people with diseases onscreen. Such efforts aim to enhance communication strategies that resonate with diverse audiences. Furthermore, transformative technologies like cell and gene therapies are gradually moving towards mainstream clinical adoption. This transition necessitates zero-tolerance logistics to ensure these complex therapies reach patients safely and effectively—a paradigm shift offering potential cures but also posing logistical challenges. Finally, industry events such as ASCO continue to spotlight cutting-edge research developments in oncology. Such conferences are pivotal in advancing treatment paradigms and fostering collaborations that drive innovation across the sector. These updates reflect a period marked by groundbreaking scientific advances and strategic initiatives poised to reshape patient care and global healthcare solutions. As companies navigate these complexities while addressing regulatory and economic challenges, maintaining a focus on innovation will be key in charting future growth trajectories within the pharmaceutical and biotech sectors.Support the show

In today's episode of Trending Middle East, President Donald Trump says the US has reached a “great settlement” with Iran and that a formal agreement could be signed within days, potentially leading to the reopening of the Strait of Hormuz. Despite that optimism, tension remains high after US forces intercept two Iranian attack drones that officials say appeared to be targeting commercial shipping in the vital waterway. We also examine the economic consequences of the conflict. The World Bank says the global economy is heading for its weakest growth since the Covid-19 pandemic, with near-zero growth expected in Gulf economies this year before a recovery in 2027 and 2028. In Dubai, Emaar Properties prepares to unveil a Dh200 billion ($55 billion) megaproject designed to house nearly 150,000 residents, in one of the largest developments announced in the emirate. And the UAE approves a new breast cancer treatment from AstraZeneca that reduced the risk of death by 56 per cent in clinical trials. The move expands treatment options for patients with advanced forms of the disease. Trending Middle East is AI-assisted, using original reporting published in The National and curated and edited by humans.

"Do nothing for us without us." According to today's guest Robyn Bussey, that operating principle is the basis for effective community health work. "You don't go into a community and dictate. You go and listen and trust and be a partner," she adds. As you'll learn in this enlightening conversation, Bussey is following that approach in her current work as Just Health Director at the Partnership for Southern Equity, an Atlanta-based nonprofit advancing racial equity and shared prosperity across the South.  On this episode of Raise the Line from Elsevier, Bussey provides illuminating  examples of community-rooted work in South Fulton County and rural Georgia, and explains why community health workers may be the most underutilized asset in addressing health disparities. This wide-ranging interview with host Michael Carrese also explores: Bussey's candid perspective on what happened to the surge of interest in health equity that occurred during COVID; Why life expectancy gains in many Southern states have lagged behind the rest of the country; Her advice to students and early-career clinicians about where they're needed most.   Mentioned in this episode:  Partnership for Southern Equity If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast

This episode covers: Cardiology This Week: A concise summary of recent studies Transcatheter treatment of tricuspid regurgitation Carcinoid heart disease Milestones: MADIT-II Trial Host: Wilfried Mullens Guests: Stephan Baldus, Heidi Connolly and Konstantinos Koskinas Want to watch that episode? Go to: https://esc365.escardio.org/event/2560 Want to watch that extended interview on transcatheter treatment of tricuspid regurgitation, go to: https://esc365.escardio.org/event/2560?resource=interview   Disclaimer  ESC TV Today is supported by Novartis and Novo Nordisk through an independent funding. The programme has not been influenced in any way by its funding partners. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. All declarations of interest are listed at the end of the episode. The ESC is not liable for any translated content of this video. The English language always prevails. ESC TV Today uses a range of tools and resources (including AI) to support content production. All content is reviewed and approved by the editorial team. Statements and opinions expressed by guest speakers are their own.   Declarations of interests Stephan Achenbach, Yasmina Bououdina, Heidi Connolly, Nicolle Kraenkel and Wilfried Mullens have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Novo Nordisk, Pfizer, Sanofi, Servier, Takeda, Tecnimede, Viatris. Stephan Baldus has declared to have potential conflicts of interest to report: research grant from Abbott, lecture fees from Abbott and Edwards. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder MyCardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Abbott Vascular, Bristol Myers Squibb, Daiichi Sankyo, Edwards Lifesciences, Novo Nordisk, Sanofi Aventis, Terumo. David Duncker has declared to have potential conflicts of interest to report: lecture honoraria from Abbott, Astra Zeneca, Biotronik, Boehringer Ingelheim, Boston Scientifics, Bristol Meyers Squibb, CVRx, Daiichi Sankyo, Medtronic, Microport, Pfizer, Sanofi, Zoll. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Felix Mahfoud has declared to have potential conflicts of interest to report: research grants from Deutsche Forschungsgemeinschaft (SFB TRR219), Deutsche Gesellschaft für Kardiologie (DGK), Deutsche Herzstiftung, Ablative Solutions, ReCor Medical. Consulting fees, payment honoraria lectures, presentations, speaker, support travel costs: Ablative Solutions, Astra-Zeneca, Novartis, Inari, Recor Medical, Medtronic, Philips, Merck. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

Host: Wilfried Mullens Guest: Stephan Baldus Want to watch that extended interview, go to: https://esc365.escardio.org/event/2560?resource=interview Want to watch that entire episode? Go to: https://esc365.escardio.org/event/2560   Disclaimer ESC TV Today is supported by Novartis and Novo Nordisk through an independent funding. The programme has not been influenced in any way by its funding partners. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. All declarations of interest are listed at the end of the episode. The ESC is not liable for any translated content of this video. The English language always prevails. ESC TV Today uses a range of tools and resources (including AI) to support content production. All content is reviewed and approved by the editorial team. Statements and opinions expressed by guest speakers are their own.   Declarations of interests Stephan Achenbach, Yasmina Bououdina, Nicolle Kraenkel and Wilfried Mullens have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Novo Nordisk, Pfizer, Sanofi, Servier, Takeda, Tecnimede, Viatris. Stephan Baldus has declared to have potential conflicts of interest to report: research grant from Abbott, lecture fees from Abbott and Edwards. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder MyCardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Abbott Vascular, Bristol Myers Squibb, Daiichi Sankyo, Edwards Lifesciences, Novo Nordisk, Sanofi Aventis, Terumo. David Duncker has declared to have potential conflicts of interest to report: lecture honoraria from Abbott, Astra Zeneca, Biotronik, Boehringer Ingelheim, Boston Scientifics, Bristol Meyers Squibb, CVRx, Daiichi Sankyo, Medtronic, Microport, Pfizer, Sanofi, Zoll. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Felix Mahfoud has declared to have potential conflicts of interest to report: research grants from Deutsche Forschungsgemeinschaft (SFB TRR219), Deutsche Gesellschaft für Kardiologie (DGK), Deutsche Herzstiftung, Ablative Solutions, ReCor Medical. Consulting fees, payment honoraria lectures, presentations, speaker, support travel costs: Ablative Solutions, Astra-Zeneca, Novartis, Inari, Recor Medical, Medtronic, Philips, Merck. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

What can the rest of the world learn from one of Europe's most impressive digital health ecosystems? This week on Pulse: Amplify, Louise and George sit down with Inma Rodríguez, Market Intelligence Manager at ACCIÓ (Catalonia Trade & Investment), who led the Digital Health in Catalonia Report 2026 — a rare regional analysis that benchmarks Catalonia against the US, Asia and the rest of Europe.Inma unpacks where Europe really sits in the global market (and whether it's keeping pace or falling behind), why digital health growth is settling into a more mature ~5% a year, and whether Europe's focus on regulation, interoperability and data governance is a brake or a long-term advantage. She explains how Catalonia became the 4th region in the world for foreign health-innovation investment, the role anchor investors like AstraZeneca play, and why 65% of the region's digital health companies are building with AI. The conversation also turns to the honest gap revealed in Catalonia's hospital survey — strong ambition, moderate maturity — and the cultural, budget and patient-habit barriers slowing real-world implementation. Inma closes with the seven trends shaping 2026, why AI, personalised medicine and health data spaces top her list, and the 2030 headline she most wants to see.A data-rich conversation for anyone who wants evidence, not hype, about where digital health is heading.Stryker Vocera's Initial Delays Diagnosis Quiz LinkCheck out the ACCIO Report hereConnect with Inma on LinkedInVisit Pulse+IT.news to subscribe to breaking digital news, weekly newsletters and a rich treasure trove of archival material. People in the know, get their news from Pulse+IT – Your leading voice in digital health news.Follow us on LinkedIn Louise | George | Pulse+ITFollow us on BlueSky Louise | George | Pulse+ITSend us your questions pulsepod@pulseit.newsProduction by Octopod Productions | Ivan Juric

Oncology drug development is becoming more complex, and bioanalysis can no longer be treated as simple drug measurement.Sponsored by Leucentra, https://leucentra.com/Inspired by science, empowered by IT. Leucentra helps life science and healthcare organizations evaluate, implement, and get more value from technology that supports innovation.In this episode of BioTalk Unzipped, Gregory Austin and Dr. Chad Briscoe speak with Dr. Lakshmi Amaravadi, Head of Oncology Bioanalysis at AstraZeneca, live from AAPS PharmSci 360 in San Antonio.Dr. Amaravadi unpacks why biomarker validation is not one-size-fits-all, how context of use should guide scientific decision making, and why fit-for-purpose validation matters in modern oncology drug development.The conversation explores:00:00 Why oncology bioanalysis is becoming more complex02:12 FDA biomarker validation guidance and industry response04:27 What “fit for purpose” means in practice06:38 PK assay validation vs biomarker assay validation07:52 What drives Dr. Amaravadi's work in translational science10:48 Why validation is not a checkbox exercise12:19 Advice for young scientists entering bioanalysis15:12 Why oncology drug development is uniquely complex18:17 ADCs, bispecifics, T-cell engagers, and conditional T-cell engagers19:38 Why bioanalysis now requires understanding biology20:46 Dr. Amaravadi's path from molecular biology to bioanalysis24:34 Critical reagent management in complex oncology assays26:42 Validation, qualification, and context of use29:03 Final thoughts from AAPS PharmSci 360This episode is especially relevant for scientists, bioanalytical leaders, translational researchers, clinical pharmacologists, oncology development teams, biomarker scientists, and anyone working at the intersection of drug development, assay validation, and precision medicine.Dr. Amaravadi discusses how oncology programs now involve ADCs, bispecifics, T-cell engagers, conditional T-cell engagers, complex linkers, multiple measurable species, immunogenicity considerations, and biomarker strategies that require deeper biological understanding. As she explains in the episode, the future of oncology bioanalysis is not simply measuring what is present. It is understanding what the measurement means in the context of the biology and the development decision.Follow BioTalk Unzipped for conversations with leaders in biotech, pharma, bioanalysis, clinical development, translational science, regulatory strategy, and the future of medicine.GuestDr. Lakshmi Amaravadihttps://www.linkedin.com/in/lakshmi-amaravadi/HostsGregory Austinhttps://www.linkedin.com/in/gregoryaustin1/Dr. Chad Briscoehttps://www.linkedin.com/in/chadbriscoe/Sponsor: LeucentraRelated LinksCelerionhttps://www.celerion.com/

In 2011, Stéphane Bancel walked away from the security of leading a 6,000-person diagnostics company to join a startup of about 50 people, built on an idea most scientists had dismissed: that messenger RNA could become medicine. Almost everyone told him not to do it. He gave the bet roughly a five percent chance. Nine years later, that same bet helped the world face a pandemic in 63 days.Stéphane Bancel is the Chief Executive Officer of Moderna. Under his leadership the company designed a COVID-19 vaccine on a computer within days of the genetic sequence being posted, delivered the first dose to a human just 63 days later, and scaled from zero manufacturing to a billion doses in twelve months. Today Moderna is building personalized cancer vaccines and using AI to reinvent how medicines are discovered and made.This conversation sits right at the heart of what I believe about leadership. That the chief executive is really the chief energy officer. That the boldest decisions are rarely about appetite for risk, they are about the asymmetry between what you could give the world and what you could actually lose. Stéphane lives both, and he is refreshingly honest about the storms, the doubts and the mistakes along the way.In our conversation, we explore: → The five percent bet: how he weighed an enormous upside against a manageable downside, and why his wife was the only one who said yes → What sailing without GPS taught him about staying calm when the storm hits, and why a storm always passes → The 63-day sprint, and the Sunday phone call that saved the manufacturing of a billion doses → Why he slowed a trial down so it would be a vaccine for the world, not a vaccine for white people → The future he sees: personalized cancer vaccines, the human body mapped in silico, and why he calls chemotherapy tomorrow's barbaric history“I still believe that we have not invented yet our best drug.” Stéphane Bancel, CEO of ModernaIf you have ever faced a decision that everyone around you called too risky, this one is about how to think, and how to stay calm, when you choose to leap anyway.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. The landscape of these industries is one of constant evolution, characterized by scientific advancements, strategic mergers, and regulatory maneuvers that shape the future of healthcare. In a significant scientific breakthrough, Merck & Co. and Gilead Sciences have made strides in HIV treatment with the development of a weekly pill. This innovative regimen combines Merck's islatravir with Gilead's lenacapavir, showing promise in two phase 3 trials. If approved, this long-acting oral therapy could revolutionize HIV care by offering a more convenient dosing schedule, potentially improving patient adherence and outcomes substantially. This novel regimen signifies progress towards simplifying HIV treatments with once-weekly dosing. Meanwhile, in the oncology sector, Gilead's Trodelvy faced challenges when combined with Merck's Keytruda as a first-line treatment for PD-L1-high non-small cell lung cancer. The phase 3 EVOKE-03 trial was terminated, shifting attention to competitors like AstraZeneca and Daiichi Sankyo, who continue to advance their own therapies in this area. In a strategic move to bolster its position in lung cancer treatment, GlaxoSmithKline (GSK) is acquiring Nuvalent for $10.6 billion, aiming to secure near-approval cancer therapies capable of challenging market leaders like Roche and Pfizer. This acquisition underscores the focus on targeted cancer therapies that increase treatment efficacy by honing in on specific genetic markers. Nuvalent's innovative pipeline of small molecule inhibitors targets drug resistance and mutations in cancer treatment—a strategic addition to GSK's portfolio aimed at enhancing its position amidst rapid advancements and intense competition in oncology. In diabetes and obesity management, Eli Lilly is advancing with its new oral GLP-1 receptor agonist, Foundayo (orforglipron), which has shown competitive efficacy over oral semaglutide. Analysts see Lilly's progress as strengthening its leadership in the growing obesity drug market. Similarly, AstraZeneca is making progress with its own GLP-1 candidate, elecoglipron, as phase 2 data sets the stage for pivotal studies. Promising clinical trial data from Eli Lilly's retatrutide for obesity-related conditions and AstraZeneca's elecoglipron suggest a strengthening pipeline for GLP-1 receptor agonists known for their dual effects on weight management and glycemic control. On the diagnostics front, Roche reaffirms its €600 million investment in Germany amid industry retrenchments by companies like Eli Lilly and Boehringer Ingelheim. However, Roche remains cautious about future risks due to shifting economic conditions. The financial dynamics within biotech are also noteworthy. Parabilis Medicines is planning a potentially record-setting IPO following Kailera Therapeutics' successful public offering earlier this year. These trends indicate strong investor confidence and an influx of funding towards innovative cancer therapies. Meanwhile, CeQur's $100 million Series E funding round aims at accelerating insulin patch delivery systems' commercial growth—highlighting ongoing innovation in diabetes management solutions. Regulatory updates reveal AstraZeneca facing reprimands from the UK marketing watchdog due to repeated breaches related to LinkedIn activities—an ongoing challenge in pharmaceutical marketing compliance. The integration of digital health solutions continues apace as ixlayer partners with Vertex Pharmaceuticals to launch a digital acute pain management platform. This initiative aims at improving patient care by reducing reliance on opioid-based treatments. These developments paint a picture of an industry where scientific innovations, regulatory hurdles, and technological advancements intersect to shape future therapeutic landscapes. Precision oncology is another area witnessing substantial growth. The landscape also sees notable activity in rare disease therapeutics. Johnson & Johnson's Talvey has gained acceptance in Scotland for treating relapsed multiple myeloma using bispecific antibody technology—a trend toward leveraging immune system targeting technologies to enhance cancer treatment efficacy. Moreover, Zai Lab's Tivdak received approval from China's NMPA for cervical cancer treatment based on Phase 3 data, highlighting the rise of antibody-drug conjugates (ADCs) as potent oncology therapies due to their targeted delivery mechanisms. On the research collaboration front, AlzeCure Pharma's partnership with Eli Lilly focuses on Alzheimer's disease research through Alzstatin ACD680—a small molecule targeting neurodegenerative pathways—a testament to the collaborative efforts needed to tackle complex diseases like Alzheimer's. However, challenges persist as Bial discontinued its GCase activator program after failing Phase 2b trials for Parkinson's patients with GBA1 variants—a stark reminder of the high-risk nature inherent in drug development despite initial promise. These myriad developments underscore a vibrant period within pharmaceutical and biotech sectors where scientific advancements rapidly translate into actionable therapies promising substantial improvements in patient care by addressing unmet medical needs globally.Support the show

Everything came up roses for Eli Lilly at the American Diabetes Association, as the pharma boasted positive results for its new pill Foundayo and next-gen asset retatrutide—not just for weight loss but also for other indications.Obesity rival Novo Nordisk, meanwhile, held a dinner, during which executives may have convinced analysts that the company is turning a corner after a rough couple of years.Also check out ADA updates from Roche and partner Zealand Pharma, Boehringer Ingleheim, Pfizer (touting results from its Metsera buy), AstraZeneca, Kailera Therapeutics and more.Outside of ADA, the biggest news of the past week came on Tuesday with GSK striking the biggest traditional pharma/biotech M&A of the year so far with its $10.6 billion acquisition of oncology focused Nuvalent Bio. And on Monday, J&J notched a smaller deal, buying out Firefly Bio for $1B. These deals add to continued uptick in M&A seen in biopharma this year, with much of that momentum being driven by Eli Lilly and its GLP-1 cash.At an FDA listening meeting last week on the Commissioner's National Priority Voucher program, the agency heard multiple calls to pause it. Confusion also still persists around all of the new rare disease pathways, including the new plausible mechanism framework.

“I think it’s the most exciting period in cancer discovery and development that I’ve experienced over the last 25 years,” says Susan Galbraith, executive vice president of oncology R&D at AstraZeneca. Galbraith joins Bloomberg Intelligence analyst Sam Fazeli fresh from the ASCO conference to unpack how ctDNA, earlier intervention and next-generation oncology platforms could reshape cancer care. They discuss AstraZeneca’s Stride regimen in liver cancer, Serena-6 in breast cancer, progress in pancreatic cancer and the company’s push across ADCs, bispecifics, CAR-T and radio conjugates.See omnystudio.com/listener for privacy information.

Rheinmetall, Kering, GSK, AstraZeneca... bajo la lupa de Alberto Roldán, profesor de finanzas de la Universodad Europea

Las acciones tecnológicas repuntan gracias a las compras en las caídas, lideradas por ASML, Infineon o Nvidia. Eso pese a que el aumento de los rendimientos de los bonos y la persistencia de la inflación incitan a la cautela entre los inversores, según señalan los analistas de BofA. Los precios del petróleo caen tras el acuerdo entre Israel e Irán para detener los ataques; el Brent baja un 1,75%. Sector a seguir hoy el farmacéutico. Con GSK y AstraZeneca de titulares. Por ello preguntamos a Mar Jiménez, de DiverInvest. En Bolsa española, y dentro del Ibex35, lideran las subidas Solaria, Puig y Colonial. Al frente de los recortes se ponen ArcelorMittal, Rovi y Grifols.

Description The Future of Tech is Here. Subscribe to our Newsletter:https://theultimatepartner.com/ebook-subscribe/ Check Out UPX:https://theultimatepartner.com/experience/ In this presentation from Ultimate Partner Live, industry analyst Jay McBain breaks down the monumental macroeconomic shifts rewriting the tech sector in 2026. https://youtu.be/r0qTDyw97Gs As the industry rapidly approaches a $6.07 trillion valuation, driven by massive AI infrastructure investments from Sam Altman and the “Magnificent Seven,” traditional sales and channel models are fundamentally collapsing. McBain reveals how buyer demographics have transformed to an integration-first millennial base, why marketplace ecosystems now command over half of all partner-funded deals, and how a tiny elite of just 1,000 tech service providers control two-thirds of global tech revenue. Learn the exact mechanics behind how Microsoft out-partnered AWS to win 26 straight quarters of dominant growth and how your business can deploy an algorithmic early warning system to capture massive wallet share before competitors even step into the boardroom. Key Takeaways Over half of the Fortune 500 companies vanish every 20 years because their leadership fails to anticipate macroeconomic technological cycles. The true opportunity in the $6.5 trillion AI boom lies not in single vendor products, but in the hardware, software, services, and telecom ecosystem surrounding them. Indirect tech sales are undergoing a structural shift toward direct cloud hyperscaler models driven heavily by Nvidia's core infrastructure client base. Modern business deals are won or lost months before the point of sale based on the average of 6.3 partners surrounding a customer’s environment. Over 51% of tech buyers are now millennials who prioritize software integration capabilities and digital marketplaces over traditional human sales interactions. Tech service economics are pivoting aggressively away from upfront margins toward point-based multi-partner funding across subscription cycles. If you're ready to lead through change, elevate your business, and achieve extraordinary outcomes through the power of partnership—this is your community. At Ultimate Partner® we want leaders like you to join us in the Ultimate Partner Experience – where transformation begins. Key Tags Nvidia AI buildout, $7 trillion AI opportunity, cloud ecosystem decade, Microsoft vs AWS growth, multi-partner cloud deals, digital marketplace migration, millennial B2B buyers, B2B tech subscription economics, tokenized micro consumption, tech services wallet share, hybrid cloud infrastructure, 28 customer moments, IT services industry growth, telecom spend breakdown, channel chief strategy, managed service providers MSP, global systems integrators GSI, software integration first, point-based vendor incentives, automated co-selling workflows Transcript JAY McBAIN AUDIO PODCAST [00:00:00] Jay McBain: So to go back to that story about the 53% of companies who are gonna fail, one of us is gonna be asked to write the book, but chapter one is always you Blame the CEO. [00:00:13] Vince Menzione: We just came back from Ultimate Partner live in Bellevue, Washington, where we hosted incredible leaders for two amazing days. Come join us for this next session where we explore the tectonic shifts we’ve all been seeing. With that, I am incredibly blessed to invite a friend of mine to the stage. I have a quick little side note, like I found an old LinkedIn post from this gentleman from like many years ago, like 20 years ago. [00:00:39] Vince Menzione: And I wasn’t really that nice to you on that LinkedIn post. Like, oh, like this is before Jay became the Jay, that we all know Jay to be j. But he was in the space and I was at Microsoft doing something and he reached out about something. It was kind of rude, Jay. I was like, oh my gosh. I can’t believe. But Jay has been a great friend. [00:00:54] Vince Menzione: When we started the podcast back up, uh, during COVID we started doing podcasts together. When we moved to the studio, Jay was the first person in the studio. He’s always got a spot, uh, at our events. He’s s Spot Art, and, and he’s a great friend and supporter of Ultimate Partner Jay McBain. For those of you who don’t know him, Jay, welcome. [00:01:13] Vince Menzione: Thank you, sir. [00:01:22] Jay McBain: 31 days ago, we landed Artemis two. The furthest humans have ever been away from the planet Earth 57 years ago. We landed on the moon in the 56 years. Between those two moments, the tech industry has been the fastest growing industry in the world. Every single year we moved from the space race to the technology race, and we’re just getting started. [00:01:46] Jay McBain: If you’re old enough, you’ll recognize the mainframe and mini era for 20 years. You’ll recognize a young disheveled Bill Gates showing up in Boca Raton, Florida for, uh, August the 12th, 1981 launch, where Bill thought that every one of us would’ve a PC in our home, and IBM thought they were gonna sell 10,000 of them to hobbyists. [00:02:12] Jay McBain: 1999, a small startup from an executive who just left Oracle in San Francisco named Mark Benioff. A couple of years later, Jeff Bezos went into a boardroom and said, listen, we’ve spent a lot of money building infrastructure to our busiest day, Christmas, black Friday. You’re telling me this stuff sits idle 10 or 20% for the rest of the year. [00:02:35] Jay McBain: Why don’t we rent that out to others? Got laughed outta that boardroom and then got made of fun of on magazine covers. Maybe you should just tend the store, let the adults talk about technology. In March of 2023, our neighbors, our friends, our family saw DeepFakes. They saw poetry, they saw music, and they came to us as tech people and said, did we just light up Skynet? [00:03:03] Jay McBain: Now every one of these 20 year eras, this is the Taylor Swift version of our industry. Every single one of these eras triggers the fastest growing product in history. Today it’s actually Chacha bt first to a billion users. It triggers a new, richest person in the world, bill Gates, to Jeff Bezos. Now, Elon Musk is the first to sign a trillion dollar pay package, and it’s not for car. [00:03:27] Jay McBain: It’s not for cars. It also triggers a most valuable company in the world change. And today that’s nvidia. These are monumental changes in our industry and they’re monumental changes in partnering every single time. And it also links to our customers. If you take a 20 year view of business, one era, and, and think about the AI era, you know, at the start of it here, if you’re to grab the Fortune 500 magazine from 20 years ago and start to flip through it, 53% of the companies in there no longer exist. [00:04:06] Jay McBain: Every 20 year cycle, we lose over half of the biggest companies in the world. These are the companies that have very deep pockets to buy their way outta problems. If you’re not in the Fortune 571% of tech companies don’t make it 10 years. These are the changes that cost industries. There are changes that cost really big companies and the decisions we make, the trends we’re in right now, in 2026 will be written about in the future. [00:04:39] Jay McBain: This new era, a lot of big numbers being thrown around. Vince’s best friend talk about a six and a half trillion dollar AI opportunity, but it’s not Microsoft’s tam. Microsoft is chasing about a trillion dollars of this. And the ecosystem, the hardware, the software, the services, the telecom is gonna make up the rest. [00:05:04] Jay McBain: It is an ecosystem. Every time these big numbers are thrown, the word ecosystem is always thrown around it. Not to be outdone, Sam Altman’s talking about a $7 trillion build out. The world economy this year, the world GDP will be 126. These are material numbers to world GDP, but even better, they’re both larger than our entire industry is today. [00:05:27] Jay McBain: So what took 56 years of the fastest growing industry this year will be $6.07 trillion. Big numbers, but it’s easier to think about it in terms of a dollar that our customers spend in that dollar. They’re gonna spend 25 cents on hardware. They’re gonna spend 25 cents on software. So for anyone that read the memo 15 years ago, that software’s gonna eat the world, there’s still a dollar a hardware to run every dollar of that software. [00:05:57] Jay McBain: And whether you’re thinking humanoid robots or whichever future you’re envisioning, there’s going to be a dollar of hardware to run every dollar of software for the next 20 years. There’s over 25 cents now in IT services, and in many cases, these services are growing faster than the product categories and just under 25 cents in telecom, that’s how it breaks out today. [00:06:19] Jay McBain: And this industry, which took 56 years to get to this point, is gonna double in size in the next three to five years. We already have two and a half trillion of that seven raised and being spent. Part of the reason Nvidia is the most valuable company in the world. Now our industry, uh, you talk about ultimate partnerships. [00:06:40] Jay McBain: Our industry traditionally, and world trade by the way, is 75% indirect. The dealerships, the agencies, the brokers, the resellers, the retailers, the franchisees, the gas stations, the grocery stores, the pharmacies, all 27 industries sell indirect. You gotta think back the last time you bought something direct. [00:07:01] Jay McBain: Well, I bought a Dell from that dude in the nineties. Cool. Well, Dell Technologies is now 60% indirect. Well, I bought insurance. Direct is 15 minutes. Could save me 15%. Well, Geico last year sold more insurance through agencies and brokers than they did direct. This is the world now. We used to be 75% indirect four years ago. [00:07:26] Jay McBain: Then it went to 73.2, then it went to 70.1 and it then it went to 66.7. By the way, marketplace is in these numbers indirect. It’s not marketplace causing this change. It’s one company, Nvidia. Nvidia has seven customers. The magnificent seven, uh, half of them are in the room right now that every morning we wake up to a hundred billion dollars press release about this $7 trillion buildout. [00:07:56] Jay McBain: What’s interesting is indirect sales in our industry is growing by revenue. It increases every year, just not at the pace that this AI build out is happening direct with seven companies. But the reason we’re all here, and I think the core reason that Vince is building this community is this, you know, Microsoft forever has measured and been very vocal. [00:08:21] Jay McBain: About 96% of their deals have partners in them. Kind of who cares, who collects the money. We care about the moments, the 28 moments before the customer makes a purchase. We care about every 30 days forever, because two thirds of our industry, over $4 trillion now is subscription consumption based. Winning a customer today is only winning the first 30 days. [00:08:46] Jay McBain: We care about this cycle. We care about who surrounds our customer. So six years ago, I stood on a big stage and said, you know, we went through a decade of sales. You know, in 1999, you thought you were born to be a salesperson. You’re managing your territory with your gut. Well, a few years later, you were introduced to the science of selling. [00:09:07] Jay McBain: You know, 10 years later you thought as a marketer, you sit around a cocktail party joking with your friends, 50% of my marketing dollars are wasted. I just don’t know which 50%. Really funny. In 2009 until every 58-year-old CMO got replaced by a 38-year-old growth hacker. Coming in with Marketo and Eloqua and Pardot and HubSpot, and 15,505 as of yesterday, MarTech and iTech tools, ninjas in marketing, they wouldn’t let a nickel go through without measuring. [00:09:43] Jay McBain: Now we understand 96% of deals and partners that surround it. No deal is gonna be won or lost in this era without partnering effectively. So we had to have this decade of the ecosystem. One of the ways we’re tracking is by outsiders. You know, Salesforce every year publishes the state of sales and they’ve got, you know, the number one CRM in the world. [00:10:05] Jay McBain: So they get to go talk to all the CROs, all the salespeople in the world. And as of this year, a couple months ago, 94% of every salesperson in every industry in the world uses partners every single day. You wanna see what this number was six years ago. Also, 89% of salespeople around the world don’t think they’re going to club this year without partners. [00:10:29] Jay McBain: So this is a big moment for us, halfway through the decade ecosystem, but we’re only halfway through. We’re starting to understand now at a more granular level. What partnering means. It’s not theory, it’s not flywheels. It’s not really cute. McKinsey slides that we keep showing to our board saying how important partnering is. [00:10:51] Jay McBain: We’re trying to get to the very specific level of the 6.3 partners on average that surround the deal and what they’re doing. How their business model works, and that’s average if I’m working on a public sector deal. I was at a Red Hat conference yesterday talking sovereignty. If I’m in an enterprise or a large public sector deal, it’s north of 10 partners in the deal. [00:11:15] Jay McBain: So we’re starting to understand what used to be this, this, you know, you’ve been the fastest growing industry for 56 straight years. Every single professional services person in every industry has come in to join the fund. Over 90% of accountants are tech services firms. Over 90% of marketing agencies are tech services agencies. [00:11:36] Jay McBain: All of this 250,000 software companies, a million emerging comp tech companies, the half a million VAR that have been in that traditional channel. The managed service providers, all of these 20 different partner types, millions of companies, tens of millions of people competing for 6.3 spots. Around the customer. [00:11:58] Jay McBain: That’s it. Luckily, there’s 141 million global customers to compete for. There’s, there’s some open slots that you can go find, and that’s the point. Our industry never had our own Fortune 500. We always talk to, you know, these partners and GSIs are doing this and SI are doing that. And we never really had a view of capability and capacity or what our own TAM was inside of that partnering. [00:12:25] Jay McBain: And so we set out and we would’ve loved, you know, chat GPT or Gemini or Claude or any of those tools to do this. But there’s one problem in partnering with AI is that it doesn’t know one partner from the next. There’s a big digital sameness problem in our industry that every single partner, whether it’s Larry in the White van or Accenture, with 786,000 employees all say they do all things to all people all the time. [00:12:53] Jay McBain: 98% of them, 99% of them are private companies that don’t share their p and l. You can’t go into Microsoft’s LinkedIn system and find out how many employees, ’cause it’s a block system, it AI can’t see into it. So it just sees, and it’s a great pattern matching. Google, SEO can’t figure out who’s who, nor today can the large language models. [00:13:14] Jay McBain: ’cause all the things they’re trying to match, the transformers are trying to match. It all looks the same. Every tweet, every ebook, every website, every digital history looks the same. So this took us thousands of people hours across two years to do, to dig into every p and l to dig into every dollar of what they’re doing. [00:13:33] Jay McBain: But what was interesting is only a thousand partners in our industry do two thirds of all tech services. When you get into enterprise, it goes up to 80 to 90%. The partners in the middle, in Blue do more tech services. The 30 of them than the 970 partners in white on the outside, the 970 partners in White do more tech services than the next million combined. [00:14:03] Jay McBain: This is our industry in a nutshell. Every time we talk to a a vendor, every time we talk to a partner, every time we talk to a distributor, we’re now talking names, faces, and places. You you wanna talk sovereignty. Yesterday in Atlanta, 90% of sovereign conversations in public sector in the globe is handled by these companies here. [00:14:26] Jay McBain: Forget about how much you do with these partners today. You wanna chase the next column, which is the wallet share. And I was a channel chief for 17 years. I get the weekly report and I see a million dollar partner, another million dollar partner, sorted top to bottom. You don’t know which partners which, which of those million dollar partners is doing 1.2 million in your category. [00:14:46] Jay McBain: They deserve a baseball cap and a front row seat at your event as an MVP. The next partner right next to them is doing 10 million in your category. They’re only doing a million with you. ’cause customers are pulling them into it. Nine times outta 10. They’re leading with your competitor. So I don’t want that list anymore. [00:15:03] Jay McBain: I want the new list, which is showing me those $9 million opportunities. And I as a board member, as A CEO, as a CFO, as a CRO, I wanna see this list. And then I want to talk people, processes, programs, technology. What are we gonna do to go get our fair share of that 9 million? Where’s our lowest hanging fruit? [00:15:24] Jay McBain: How do we double our pipeline? How do we double the size of our company in three years? It’s all right here. Let’s have very specific conversations and move away from flywheels and move around from force multipliers and and things like that in partnering. Let’s figure out how this partner community is surrounded. [00:15:45] Jay McBain: What do 10 million people who have to be smart in front of their customers every single day, what do they read? Where do they go and who do they follow? It’s the law of a few. This is the old Malcolm Gladwell of tipping point 10 million people in the broader channel. A hundred percent of our TAM comes down to only a thousand watering holes. [00:16:08] Jay McBain: 12% of that entire audience. Doesn’t sound like a lot, but it’s over A million. People love podcasts. Number one way they learn the Joe Rogan effect. In our industry, there’s 121 podcasts. These are all public lists. You can go get on my LinkedIn newsletter on canals, oia. But there’s 121 podcasts that drive him forward. [00:16:28] Jay McBain: Really high up on that list, actually number one on the list is ultimate partner, Vince. That’s how I met. ’cause I asked people, 10 million people, you love this. You walk your dog, you drive to work, you listen to podcasts. I’m not the biggest podcast fan. It’s not number one on my list, but it’s number one on theirs. [00:16:44] Jay McBain: They say, you know, you gotta meet this guy, Vince. It’s unbelievable how great these podcasts are. They’re ultimate. [00:16:54] Jay McBain: Then I talked to Vince and said, but Vince, you know, 35% of your community, the 10 million people love to come to events like this one. The hallway conversations, the hotel lobby bar last night. This is what we love to do, especially post pandemic. It’s the number one way we learn. We learn from our peers, we learn from those around us, and, and the learn from the conversations we have here. [00:17:17] Jay McBain: We always remember these moments, you know, years and years later. There’s 352 choices. I’m going to five of them this week in five different cities. It’s a lot of coverage, but again, it’s a tighter li list of how people work. The magazine lists 106 of them associations like Conter. Now the GTIA peer groups, there’s 15 different spheres of influence, but only a thousand places. [00:17:43] Jay McBain: I could walk you through billionaire, after billionaire, after billionaire in this industry and show you how they did this. How did Arne Bellini at ConnectWise? How did Austin McCord at Datto, how did Nerdio become a unicorn? How did threat locker and huntress move away from 6,500 cyber companies and become unicorns over and over and over again? [00:18:05] Jay McBain: It’s only one slide. Unicorns and billionaires are made here, and a lot of people don’t get it. So walking away from Bellevue, a thousand partners, top down, a thousand watering holes, bottoms up. You’ve covered a hundred percent of your tam. You do it better than 10% of your competitor, 10% better than your competitors. [00:18:27] Jay McBain: You win. You carry that on your resume into the next company. You get a bigger job at a bigger pay scale. Let’s just walk through some examples. Cyber 91.7% of it goes through the channel. Huge channel audience. You know, if you’re in MarTech, it’s only 10%, but this one happens to be all channel, but that’s not the story. [00:18:48] Jay McBain: For every dollar that the 6,500 cyber companies are trying to close, there’s $2 in services. Plot twist, the products are grown at 11, the services are grown at 12.6. Your partners are growing faster than you are, and they will continue to for the next, at least five years, probably 10. So when I’m here, five years from now, you’ll hear in me talk about a three to one split in cyber and then a four to one split in cyber. [00:19:18] Jay McBain: Now, when we’re in Miami a couple days ago is CrowdStrike, they’re talking about a $7 and 5 cent multiplier, chasing that two to one up higher. You look at managed services. Here’s a fun story. Managed services. 82% of customers who are man, uh, outsourcing more this year than last year. 650 billion in size. [00:19:38] Jay McBain: This is bigger than the entire SaaS industry. Salesforce, ServiceNow, Workday, Marketo, NetSuite, HubSpot, 250,000. Others. This is bigger. It’s also bigger than all the Hyperscalers combined, not just AWS, Microsoft and Google, but Alibaba and Oracle and everybody down the list. This is a massive market also growing at double digits. [00:19:59] Jay McBain: So these are some big things and obviously we’re watching, you know, week in and week out, quarter in, quarter out, the Battle of Software and Battle of the Hyperscalers and things like that, and who’s growing at what pace and, and how partnering is connecting to all of this. You know, we watched a moment really early in the pandemic where Microsoft started growing faster than AWS and they haven’t stopped since 26 straight quarters. [00:20:27] Jay McBain: And you ask customers and say, you know, does Microsoft have a better product? And in most cases they say no. You know, AWS had a five year head start. Well, did they have a better price? Well, no, actually most cases Microsoft’s more expensive. Well, did did they have better promotion? Was their Super Bowl ad better? [00:20:44] Jay McBain: No, they’re both kind of crap. So you kind of ask the questions of what’s the only difference that could create growth above the leader in the market? Well, it’s place. More of the 6.3 partners are walking into those keyboard room meetings and drawing clouds up on the wall and labeling the Microsoft than they are AWS. [00:21:03] Jay McBain: Very simple. It’s never been about product. The best product in our industry has never won. And now the best way forward is that partnering moment, and this is the moment. So to go back to that story about the 53% of companies who are gonna fail, one of us is gonna be asked to write the book. And it could be the book like Kodak, they invented the product that ended up killing them. [00:21:26] Jay McBain: And it’s a woe is me story, but chapter one is always you blame the CEO. How could they not see those trends happening in 2026? How could they, you know, were they blind? Were they stuck in their own, you know, innovation chamber? Innovator’s dilemma, were they stuck in their own boardrooms? Why couldn’t they see? [00:21:46] Jay McBain: Well, chapter two, you, you blame the board. They have fiduciary responsibility, outsider view, and how could they not see it? But really, this is the future right here. If you take this slide and apply it 10 or 20 years from now to every failure and every success, these are the chapters of the book. Your buyer is now a millennial. [00:22:05] Jay McBain: As of last year, the 51% of our market is bought by people born after 1982. Different psychology, different behavior, different journey, different criteria, their integration. First buyers. The buy a product, 80% as good as the next one. If it works better in their environment. 94% of people won’t buy a car unless it has CarPlay or Android Auto. [00:22:26] Jay McBain: New Buyer. You have to be more integrated than your competitors. That’s a partnering story. The 6.3 partners. If you heard cyber, you need some great channel partnerships, but you need the other 5.3 partners as well, the consultants, the advisors, the designers, the architects, the implementers, the integrators, the manner service, all of the other partners. [00:22:44] Jay McBain: You need to know more of them than your competitors do, and have them label clouds with your name in them. You need better alliances. Even if you compete, you only compete in the morning. You’re best friends by the afternoon. You have to be tight with the hyperscalers, tight, with the big SaaS platforms, tight with cyber, tight with distribution, there are layers, seven layers to every deal. [00:23:04] Jay McBain: You gotta be tight in and have better alliances than your competitors. And then it all comes to the 28 moments, which I’m gonna end on, but the go to market of all of this, the co-selling, co-marketing, co-innovation, co-development, co keeping. This is it. Your product has to be good enough that somebody’s gonna renew it. [00:23:21] Jay McBain: Your Super Bowl has to be, you know, ad has to be good enough that people don’t, you know, shame you on social media. Your pricing has to be somewhere in a country mile of the bell curve of what the customer wants to pay. But successor failure is just here and platforms are synonymous with partnering. [00:23:40] Jay McBain: It’s our role now in the decade of the ecosystem to drive our companies forward. Marketplace. It’s probably the most predict, you know, great prediction we ever made. You know, growing at 82% compounded, it’s hard to predict ’cause it doubles almost every year. We were almost exact to the decimal point. Five years later now till 2030, we’re watching a second story, which is more interesting. [00:24:02] Jay McBain: If 96% of all deals have partners inside of them and there’s private offers and multi-partner offers and distributor sellers record all these funding mechanisms or services as a product. As of last week, over 50% of all deals in marketplaces now have partner funding. It means that while money changes hands differently, the respect and the recognition of what partners do is in the deal. [00:24:26] Jay McBain: We think that’s going to 59, but at some point, that’s gonna have to hit 96. ’cause to run the best programs, whether it’s an indirect sale, whether it’s a direct sale, whether it’s a marketplace deal, it doesn’t matter how money changes hands. What matters is we recognize the 6.3 partners. They’re not only making the deal happen bigger and faster, but renewing and enriching that every 30 days forever. [00:24:48] Jay McBain: When we watch, you know, billion dollar clubs and when we read all the press releases and all the hubbub about how fast this is growing and who, which companies are behind all this. When I’m quoted in some of these press releases, it’s because of this. You know, CrowdStrike, you know, brags are a billion dollars in a single year, but inside of that, they’re showing that 91% growth in marketplaces, which is pretty phenomenal for any company to almost double in size every single year. [00:25:17] Jay McBain: What’s more phenomenal is they’re growing the channel piece of it, 3548%. That green part of it is growing. Companies that understand platform and have people and processes and programs and technology to do it are winning. And they’re getting recognition and partners are starting to join the Billion Dollar Club who don’t sell a product, but are also winning at Extreme Scale. [00:25:44] Jay McBain: So talk about those partner 1000 and who are leaning in to win at this level. As well as everything changes, traditional billing moved into subscription models, moved into consumption models. Now we’re being tokenized to death multi it’s, it’s in this mode of micro consumption. There’s no chance there was little chance in subscription consumption that would be resold. [00:26:09] Jay McBain: You don’t buy Netflix from the cable guy in the white van. There’s zero chance when you’re buying tokens at a buck a piece that that’s going through any indirect sale. This continues to grow. Now the tectonic shifts is what happens when money changes hands differently. These old programs that we used to all write hundreds of different boxes, we checked every day on deal reg and trainings and all the other things are changing. [00:26:35] Jay McBain: To this, you’ll get these slides, by the way, in high res, inside of this now is the customer. For the first time ever, 45 years later, we have the customer in the middle of what we do, the 28 moments in green before they buy the seven layer stack and the partners inside it. The implementation. The integration, the managed services in a cycle that never ends, and two thirds of our industry. [00:26:55] Jay McBain: With the customer in the middle, we can now move money around to the different moments. It’s not all landing in front or backend margins or market development funds or new customer bonuses or spiffs. It’s landing where it needs to land. Over 400 companies now, pretty much led by Microsoft 400 companies are in a point system right now and 400 more. [00:27:18] Jay McBain: We’re working kind of behind the scenes to get that announced in the next 12 months. This is a total changeover in terms of how economics work and partners are yelling over half of us. I don’t care. Don’t call me a VAR anymore. Don’t call me an MSP. Don’t call me a regional system integrator. I do the consulting over half the time. [00:27:36] Jay McBain: I do the design, I do the implementations, I do the managed services, and 44% of us are vibe coding. On weekends. We’re not happy. Just on the services side. We wanna join the seven layer tech stack as well. These are partners growing faster than their vendors by understanding this cycle and where to show up and where the money is in ai. [00:27:56] Jay McBain: And the number one thing they’re asking for is not more leads, which they did for 45 years. The number one thing is now recognized for what I do. I’ve never just been a cash register. We’re completely now past this idea of a channel being a channel of distribution, and now a channel being this platform for the future. [00:28:16] Jay McBain: As we lay that on top of ai, the first couple of years of AI has really been consumer driven. The 95% failure rate that MIT reported last year is now 70%. That’s the failure to get from proof of concept to production. That 70 will be 50 by the summer we’re moving now in business, the maturity rates are going up at the end customer and in 88% of cases, that’s because of the channel. [00:28:43] Jay McBain: They’re working with partners. They’re not vibe coding themselves and working in little skunkwork groups. They’re working with partners to make it happen, and it now becomes the partner’s number one growth opportunity. I can grow at 11 or 12% in cyber every year. Compounded I can grow in 10% in managed services. [00:29:03] Jay McBain: You know, those are great double digit growth ’cause my customers are growing at 2.7% and I can go four x my customer, but I can go 10 x my customer if I have the right services built around ai. And this compounded growth rate and that big number in 2 20 32, 267 is what’s got those top 1000 partners obsessed. [00:29:25] Jay McBain: And your companies are leading with ai. Now you need to connect to those AI services. You need to get partners on this scale of growth. And they will be adding your name inside every cloud. They write on every whiteboard, but 82% of partners around the world, you know, we survey 25,000 of them aren’t ready, and they’re blaming vendors for not being ready, and they’re telling them exactly the workshops and the training that they need to get ready for this cycle. [00:29:53] Jay McBain: 82% of our entire partner, tens of millions of people, aren’t ready to grow at 35% and they need our help. Last thing I’ll say about AI is it’s the first time from client server to cloud, edge to cloud that it’s been segment driven. SMB alone has one, you know, six different segments, one to nine, 10 to 24, 25 to 49, et cetera. [00:30:18] Jay McBain: Mid-market into enterprise. No one that runs a restaurant is calling Jensen to buy a GPU to put next to the stove. No one’s calling Sam or Dario or anyone at Anthropic or OpenAI directly. They’re waiting. If you run a restaurant with all the people running around with tablets, you’ve invested in toast or square or clover or one of the platforms to run your business. [00:30:41] Jay McBain: A hundred different things. And you’re gonna wait for toast to work with a hyperscaler and build out the capabilities genetically. So when they see a spike in Uber Eats orders, they automatically place a food order and automatically change the staffing to deliver on it. That’s what the restaurant’s waiting for, and there’s no one calling and having a big a agent conversation. [00:31:03] Jay McBain: But even if you go into hundreds of people in medium sized business, every one of the vice presidents have their tech stack already built. I talked about the marketing person already, but the HR leader has one, and everybody’s got their seven layer stack. They’re not calling to buy a GPU and they’re not calling to, you know, bring in open AI directly or, or anthropic. [00:31:22] Jay McBain: They’re waiting for the platform they built to integrate together ag agenta capabilities. Everybody’s in wait mode up until enterprise and public, large public sector. So we are looking at this market and at 90% of that AI market is run by those thousand companies, and the rest of the millions of partners are helping in terms of how these businesses are gonna change at that level. [00:31:46] Jay McBain: Here’s where I end. You know, the 28 moments used to be a theory. It used to be a flywheel. How do we buy a car? [00:31:55] Vince Menzione: Well, we Google it, [00:31:57] Jay McBain: 81% of us now, 94% of us use large language models. We find out that there’s 365 brands of car. I’d have to test drive one every day of the year to get through them all. So we start narrowing these things down. [00:32:09] Jay McBain: We configure it. We put our rims on it, we color it. We download the invoice price. We download the backend rebates this month, whether I buy it in May or June, we find out what 5,000 people paid for our exact car within 50 miles of us. And then we don’t wanna go to the dealer because we know more than the salesperson, the manager ever will. [00:32:26] Jay McBain: We know what we’re gonna pay within, you know, dollars or cents. Just carvana the car. Hand me the keys. Let’s just forget the whole eight hour back and forth. I’ll get you a deal thing. I’m smarter than you in technology. Our customers are smarter than us, smarter than salespeople. That’s why 75% of millennials don’t wanna talk to a salesperson. [00:32:48] Jay McBain: They want to end digitally, and by the way, they’re not gonna send a fax after 28 digital moments. They’re gonna end on a digital marketplace. This is all demographics. It’s not hard to see where it’s going, but we’re getting into names, faces, places again. What if every dollar of your tam, the board, the CEO, runs around with their big multi-billion dollar number, they’re chasing? [00:33:09] Jay McBain: What if every single deal looks the exact same? This is a deal with AstraZeneca, A real deal, real customer spending millions of dollars. We know it starts in October, it ends in April. It’s a six month cycle. We see what they read, the MQ ls at the beginning. We see the sales demo moments. We see ISV, but we’ve never had the light blue boxes. [00:33:30] Jay McBain: What if we as a team could overlay the 6.3 partners in this deal? And when you find out a couple things. Here’s where I end. In December, five deals were one, three of them by NTT. The person at NTT probably coaches AstraZeneca’s, you know, kids’ soccer team. They probably have a cottage together at the lake. [00:33:50] Jay McBain: For the last 20 years, if the person at NTT worked at Deloitte, Deloitte would’ve run this deal. But Software One and Yash are both there, so we understand that when they were drawing clouds up on the wall in the boardroom in December, this deal was won and lost there. It was not won and lost at the point of sale. [00:34:09] Jay McBain: So what if you knew more about this and could see every dollar in your tam? You had an early warning system that this was happening. Two things jump out at this now that we’re in Bellevue. AWS was touched twice in this deal, directly in the marketing cycle and the sales cycle. AWS lost this deal. Here’s an example of Microsoft winning a deal with Microsoft never being touched. [00:34:34] Jay McBain: For some reason, NTT who won, who won AWS’s partner of the year a couple years ago led with Microsoft, so did Software one, Microsoft’s biggest reseller in Europe, and as did Yash, they all led with Microsoft and without Microsoft, knowing Microsoft took a multimillion dollar deal away from their competitors by winning in December. [00:34:53] Jay McBain: That’s one. Second. These partners didn’t just show up other than soccer and cottages. They didn’t show up in December. It went closed one in their CRM system. Back in the summer, August, September, we already knew AstraZeneca was in market, spending millions of dollars. We didn’t need them to read an ebook or go to an event to find that out. [00:35:17] Jay McBain: We knew it because it was closed one. They’re spending hundreds of thousands of dollars times five in December to know what to do at the end. This is an early warning system that’s better than any MQL, better than any SQL. And if you could give your company these level of view into their pipeline with an early warning system that I can work with those partners for months before they ever show up at the customer’s boardroom. [00:35:44] Jay McBain: This is it. Talk about 47% winners. This takes you from not only surviving the AI era to being a top five platform winner. Thank you very much. [00:36:01] Vince Menzione: Until next time, we’ll see you in person. Hopefully at our next event.

If you are worried about China taking over due to having better robots than the yanks, I got mixed messages for ya here. This was created using DeepSeek v4 Pro. Remember when DeepSeek could do the same thing as chatGPT but on shitty processors and not much RAM? All those stocks shit themselves? Oh what memories. Would have been a great time to buy NVIDIA stocks. I didn't, if you're asking....It's pretty good but it really didn't follow the instruction in the prompt that Joel Hill is Jack the Insider on the transcript. So that's a minus point. But also, this took fucking ages to generate. It's better than lots of the yankee slop but damn son this took MINUTES. So they might take over if we are patient or whatever. Enjoy the episode. ----------------------------------------------Joel Hill (Jack the Insider) and Hong Kong Jack return for a sprawling episode that tackles two of the biggest stories shaping politics in 2026. The pair open with the jaw-dropping Redbridge poll putting One Nation at 31% of the primary vote — a number that would all but wipe the National Party off the federal map and potentially deliver Anthony Albanese a strengthened majority government by splintering the right. Joel and Jack clash over whether culture-war grievances or material concerns are driving the surge, while drawing historical parallels to Joh for Canberra and the DLP split of the 1950s.The conversation then crosses hemispheres for a tour through UK chaos: Peter Mandelson's leaked dossier exposing a rudderless No. 10 under Keir Starmer, Nicola Sturgeon's estranged husband pleading guilty to embezzling SNP donations on a surreal shopping spree of Lalique salt shakers, seven Dysons, and a motorhome with four miles on the clock, and a deeply troubling police body-cam incident that has reignited the two-tier policing debate ahead of three critical by-elections.The centrepiece of the episode is a sober, hour-long deep dive into the COVID-19 pandemic and what Australia has refused to learn. The Two Jacks lay out the true death toll (perhaps 22 to 69 million globally), the devastating scale of long COVID, the vaccine rollout failures, the absurdities of hotel quarantine with rubbish bags over heads, and why governments and public health officials are desperate to avoid a Royal Commission. They close by asking whether the next pandemic will meet a population that has permanently lost trust in its leaders — and whether we'll simply repeat the mistakes of both COVID and the Spanish flu.Sport provides a lighter coda: the Carlton revival under an interim coach, James Hird's awkward candidacy at Essendon, the expanded 48-team World Cup that nobody seems excited about, and a formidable New Zealand Test side taking on England at Lord's.00:00:25 — Introduction Joel welcomes listeners to Episode 159, recorded 4 June. Today: Australian political news, a check-in on the UK, and a deep dive into the COVID-19 pandemic.00:01:21 — The Redbridge Poll: One Nation at 31% The AFR's Redbridge poll: One Nation 31%, Labor 28%, LNP 20%, Greens 12%. The two-party preferred is now being calculated as One Nation versus Labor — a seismic shift in how Australian politics is measured.00:03:12 — Not Just a Protest Vote Jack argues this is real, not a re-run of Hanson's 1990s flash-in-the-pan. The South Australian state election and the Farrah by-election suggest One Nation support is durable. Joel counters that protest votes can be expressed at the ballot box and that Australians are tiring of pluralism.00:04:09 — If One Nation Succeeds, Labor Wins The cruel irony: One Nation's rise probably delivers Labor government. The National Party could simply disappear. The DLP kept the Coalition in power for decades as an anti-Labor party; One Nation may do the reverse.00:05:46 — Scrutiny and Splintering Joel notes One Nation's policies are "two-sentence fragments" and motherhood statements. When proper scrutiny arrives, the contradictions will surface. Hanson's parliamentary attendance is as poor as imaginable.00:08:22 — The Third Rail Jack argues populists succeed because they discuss what polite society won't: immigration, culture wars, welcome to country rituals. The major parties must engage these topics or cede the ground entirely.00:11:34 — Feeling Unheard The core driver, Jack contends: voters feel sneered at and silenced by mainstream politics. It's not about flag counts, it's about being listened to.00:13:50 — What Actually Drives Votes Joel pushes back: voting determinants are the household economy, migration, climate change — not culture war trivia. Culture wars "don't amount to a hill of beans" at the ballot box.00:14:51 — The DLP Parallel Both agree the One Nation phenomenon most closely resembles the DLP split of the 1950s and 60s — a right-wing fracture that delivered Labor government after Labor government.00:17:18 — The Republic Referendum Lesson Jack recalls the 1999 republic referendum: pro-republicans split between models rather than uniting, scuppering the whole project. Voters will vote their preference even knowing it helps their enemy.00:19:32 — UK Parallels: Accommodate or Fight? Significant figures in the UK Tory party are debating whether to fight Reform or reach an accommodation. Tony Abbott recently said the Liberal Party won't criticise Pauline Hanson.00:21:48 — Joh for Canberra Redux Imre Salusinszky's comparison: this is "Joh for Canberra" all over again. But Joel notes Joh's moment lasted months; One Nation's has already lasted years.00:24:08 — State Election Previews Joel predicts the Victorian state election will be chaotic and peculiar — a government that's been in power too long, an opposition that may not be up to the task, and One Nation peeling votes from safe Labor seats. NSW will give a clearer reading.00:25:44 — Hanson "Ready to Govern" — from the Senate? Pauline Hanson announced she's ready to govern. Joel asks: shouldn't she contest a lower-house seat first? Jack recalls the only precedent: John Gorton became PM while still a senator, but had to be eased into Kooyong.00:28:20 — The Mandelson Dossier: Starmer's Empty Suit Jack's read of the leaked Mandelson documents: ministers don't know what the PM wants, there's zero respect or fear of his authority. Starmer comes across as an empty chair. One minister's text: "Every meeting with Labour MPs — it's all about who can we tax to pay benefits to other people."00:30:50 — Mandelson's Legal Peril Mandelson is under police investigation for misconduct in public office. Could face charges — the seriousness depends on whether it's mere misconduct or genuine bribery for foreign interests.00:31:49 — The Nicola Sturgeon Saga Her estranged husband has pleaded guilty to embezzling roughly £400,000 in SNP donations. The shopping list: six high-end coffee machines, seven Dyson vacuums, Lalique salt and pepper shakers, Montblanc pens, Swiss watches, an iJag, part of a Volkswagen, and a motorhome with four miles on the clock parked at his 92-year-old mother's house. Nicola claims she "didn't go in the kitchen much."00:34:20 — The BBC Interview Laura Kuenssberg's forensic interview with Sturgeon — "not quite Prince Andrew, but not much better." Sturgeon has been cleared by Police Scotland, but her reputation, already damaged by the Alex Salmond trial, is now in tatters.00:35:05 — Will He Go to Prison? £400,000 is a substantial sum. With another £600,000 unaccounted for, a custodial sentence seems likely. The money was ring-fenced for a second independence referendum push.00:36:50 — Money Laundering or Conspicuous Consumption? Joel wonders if the bizarre purchases — multiple watches on the same day — were an amateur money-laundering attempt: buy goods with SNP funds, sell them quietly for cash.00:38:23 — UK By-elections: Makerfield Looms Three by-elections on 18 June, including the critical Makerfield contest. Andy Burnham, Greater Manchester's high-profile mayor, is the tepid favourite. Low turnout could help him return to Westminster.00:39:30 — The Body-Cam Incident A white teenager accused of racially vilifying a Sikh man was stabbed — and police arrested the bleeding victim, not the attacker. Body-cam footage shows the victim saying "I can't breathe, I've been stabbed" while officers dismiss him. Joel calls the footage "just awful."00:41:22 — Two-Tier Policing Jack traces UK policing's overcorrection: after the Macpherson/Lawrence report, guidelines were rewritten so aggressively that they've produced a pattern of questionable enforcement that devastates community trust — and plays directly into Tommy Robinson's hands.00:42:08 — NSW Police on Four Corners Joel recommends the harrowing Four Corners investigation: bashings in custody, false arrests, an officer who threw body-cam footage into Sydney Harbour, and two undercover officers jailed for a savage assault. The problem today is general duties policing, not the specialist squads of the 1980s. Some command areas are far worse than others — a leadership failure.00:44:55 — Victoria Police: Under-Resourced, Not Corrupt Joel shares an anecdote: two divisional vans for 80,000 people in outer-east Melbourne. Tough work being a police officer; even tougher being a good one.The COVID-19 Reckoning00:45:09 — Why This Matters Joel sets the frame: we parked COVID in 2023 with a hangover but never understood what we'd been through. Today's episode aims to crack that problem.00:45:51 — The True Death Toll Officially: 7 million dead. But most countries stopped testing and stopped reporting cause-of-death data to the WHO. Using excess mortality, the real toll is between 22 and 69 million — at the high end, exceeding the Spanish flu.00:47:02 — Long COVID's Shadow Roughly 400 million people globally (6% of the population) have experienced long COVID. In Australia alone, between 200,000 and 500,000 people are living with or have lived with the condition. Second infections can be worse. Emerging links to cardiovascular disease, type 2 diabetes, and accelerated dementia.00:49:43 — The Collective Amnesia Governments worldwide have "a collective embarrassment" about how they handled the pandemic, Jack says. They want it in the history books and forgotten. Joel says this is a grave mistake for public trust — and for public health, given COVID is now a permanent fixture alongside flu season.00:50:50 — Why Excess Deaths Are the Only Honest Metric All other figures are "kind of made up" because attribution methods vary wildly between countries. Excess deaths remain elevated in Australia and most nations.00:51:25 — Children and COVID Bobby Kennedy Jr. removed under-18s from government-supported vaccines in the US. Joel argues this is a disastrous move given mounting evidence that childhood COVID infection leads to higher rates of long-term chronic illness.00:52:47 — Why No Royal Commission? Not just politicians protecting themselves — public health officials and much of the media wanted to avoid scrutiny of their judgments and actions during the pandemic.00:53:32 — The Media's Abdication Jack watched "a lot" of Daniel Andrews's daily press conferences. Only two journalists ever asked pertinent questions: Rachel Baxendale and Leigh Sales. Nobody asked why curfews, why beach arrests, why the disparate impact on tradies and cafe owners while the "laptop class" actually made money working from home.00:56:14 — Andrews's Immense Popularity Joel adds context: Andrews was wildly popular at the time, which partly explains the media's deference — though Jack insists that shouldn't have mattered.00:57:34 — The Curfew Nonsense Curfews were about giving law enforcement the easiest possible environment, Joel says — and should have been acknowledged as such and wound back sooner. Meanwhile, Bondi's wealthy swam en masse while Western Sydney's working-class communities were treated harshly.00:57:59 — The Vaccine Rollout Failure The Morrison government bet everything on AstraZeneca — the non-mRNA, first-available vaccine. Then rare blood-clotting issues emerged (seven deaths, mainly men aged 40–49). Meanwhile, Australia was left waiting for Pfizer and other mRNA vaccines because no other supply deals had been secured.00:59:37 — Omicron Breaks the Pandemic's Back The Omicron variant emerged from South Africa: more infectious but far less lethal. Combined with 95%+ vaccination rates among Australians over 18, it effectively ended the acute phase — though at the cost of entrenched mistrust.01:00:38 — Government Overreach and Broken Trust Jack's core criticism: governments outsourced decision-making to public health officials rather than making political judgments that balanced competing interests. Joel counters that it would have been a "bold move" for politicians with no scientific background to contradict public health advice.01:02:19 — "Just Let It Rip" Was Never an Option The three countries with the highest COVID mortality — Brazil (highest), United States (second), India (third) — were all led by populist governments that largely refused mandates. Letting it rip was devastating.01:03:27 — The ADF Quarantine Scandal Scott Morrison refused to allow ADF quarantine facilities to be used for returning travellers. Instead, people were crammed into hotels with gaps under the doors. Joel recalls the "rubbish bags over heads" episode in Victoria — dark green plastic bags as infection control.01:05:00 — The Inquiry's Recommendations Create a proper Australian CDC. Release expert advice publicly. Better national planning with clear political accountability. And critically: politicians must own the big decisions on freedoms and spending instead of hiding behind experts.01:06:01 — The Next Pandemic There will be another one. If it's a respiratory, airborne pathogen like COVID, similar circumstances will return. Are we ready? Probably not. Will we close the country again? The economic damage — unemployment hitting 7.5% in 2020 — was enormous, even if it recovered to 3.5% by pandemic's end.01:08:06 — Who Was Left Behind? The arts community was inexplicably excluded from JobSeeker and JobKeeper. Meanwhile, the "laptop class" working from home effectively got a 15% pay rise by eliminating commuting costs. Bunnings did very well; so did companies that kept JobKeeper without passing it to employees.01:11:14 — The Human Cost of Lockdowns Public housing towers in Flemington were locked down. Joel recalls one family: an African-Australian single mother with nine children in a two-bedroom commission flat, trapped. Jack calls what happened with schools "disgraceful." But Joel notes the evidence now shows childhood COVID infection has serious long-term health consequences, complicating the retrospective judgment.01:13:59 — Will We Learn Anything? Jack's bleak prediction: the next pandemic is probably far enough away that we'll take no notice of COVID's lessons and make the same mistakes. Joel agrees — we didn't learn from the Spanish flu a century ago either.01:15:51 — Malcolm Roberts and Vaccine Misinformation The One Nation senator claims 70,000 Australians died from COVID vaccines — a figure with no evidentiary support, built by misattributing excess deaths. In reality, mRNA technology is now being deployed as a cancer treatment, showing promise against bowel and pancreatic cancers.01:17:36 — Trust Destroyed If the next pandemic arrives within this generation, governments will face a population that has lost faith. If it takes 50 years, the damage may have faded. Western Australia, meanwhile, locked itself down with negligible deaths and actually loved the isolation — provided the iron ore and LNG ships kept moving.01:20:37 — The Spanish Flu Echo Joel's closing historical note: Australia's response to the Spanish flu in 1919–1921 was nearly identical to COVID — lockdown disputes, police arresting people for not wearing masks, states fighting the newly created federal Department of Health. The whole thing collapsed into acrimony the moment state rivalries flared. A century later, nothing had changed.01:21:48 — Federation as Fatal Flaw Jack adds: the three high-mortality COVID countries (US, Brazil, India) share a feature beyond populist leaders — they're all federations where central government power is limited. When "the emperor is far away and the mountains are high," coordinated pandemic response is nearly impossible.01:23:40 — No Appetite for Truth Jack's final word: nobody wants a proper inquiry. Not politicians, not public health officials, not much of the media. Joel disagrees on the importance — the pandemic's legacy still shapes how Australians think, vote, and trust.Sport01:27:40 — AFL Coaching Carousel Essendon and Carlton both need permanent coaches. Joel asks: is James Hird the right man for Essendon? Jack: 17 other clubs wouldn't give him an interview, but the Bombers may have backed themselves into a corner where appointing him is the only way out.01:28:53 — Merit vs Member Sentiment Rowan Connolly's question: would you take James Hird or John Longmire (five grand finals, one premiership, 60%+ win rate)? The answer is obvious on merit — but members and fans want the fairy tale.01:29:47 — Carlton's Astonishing Revival Three straight wins. Ranked 16th in forward-50 entries a month ago; now second. The game style is unrecognisable — no more bombing the ball to non-existent power forwards. Mitch McGovern's low, flat kick to Patrick Cripps for the match-winner against Geelong was emblematic of the transformation. Seven players aged 21 or younger are now getting games and bringing energy.01:33:18 — FIFA World Cup 2026: Nobody's Excited Expanded to 48 teams, Scotland are going — and a Scot in his 30s told Jack that neither he nor any of his mates (all doing well financially, normally first on the plane) have any interest. Ticket prices are "extraordinary." The final is at MetLife Stadium in New Jersey — which Jack describes as "Waverley on steroids, but even more bleak."01:36:08 — Australia's Draw Socceroos face Turkey first up, then the United States. Jack suggests marketing it as "Gallipoli Round Two." Spain are favourites; England, Brazil, and Germany are in the chasing pack.01:37:06 — Cricket: England v New Zealand, First Test at Lord's Joel runs through New Zealand's likely top seven — Latham, Conway, Williamson, Ravindra, Mitchell, Blundell — noting the first four have all made Test double-centuries. "Just about the best first six in Test cricket." With O'Rourke's express pace and Henry's quality, this is a formidable Black Caps side.01:38:40 — Stump Speech & Next Week Listener mail (including an "exposé of who Jack is") held over for next episode. For the record: Hong Kong Jack's CV includes HSC at Assumption College Kilmore, a stint as a carpenter, a law degree from Melbourne University, stints at Holding Redlich and Slater & Gordon, work as a litigation and immigration lawyer, and an appointment to the Refugee Review Tribunal as a federal cabinet appointee.01:40:39 — Outro Joel thanks listeners for hanging in for an extra ten minutes. Back next week.The Two Jacks is recorded weekly. Send your questions and feedback to the show.

Welcome back to Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives!In this special episode recorded live at the American Diabetes Association (ADA) Scientific Sessions 2026 in New Orleans, Louisiana, cohosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, welcome Ketan Dhatariya, MD, PhD, MS, consultant physician at Norfolk and Norwich University Hospitals, to discuss the evolving landscape of diabetes care, technology access, and clinical implementation. To begin the episode, Dhatariya shares his perspective on the challenges facing diabetologists, including workforce pressures, specialist training, and the difficulty of translating rapidly expanding diabetes guidelines and innovations into everyday clinical practice. The conversation then shifts to the differences between healthcare systems and how those structures influence access to diabetes therapies. Dhatariya discusses the UK's publicly funded healthcare model and the ongoing challenge of balancing the cost of emerging medications and technologies with their long-term benefits. He highlights the importance of demonstrating that investments in diabetes care today can reduce complications and healthcare costs in the future.Dhatariya then reviews the progress of continuous glucose monitoring (CGM) and automated insulin delivery (AID) adoption in the UK. He explains that CGM use among people with type 1 diabetes has become widespread, particularly among children, and that access to closed-loop systems continues to expand through structured implementation plans. He emphasizes the meaningful improvements these technologies have provided, including better glycemic outcomes among children and pregnant individuals, who may experience significant benefits from improved glucose management.The discussion explores how diabetes technology can support people with different lifestyles and challenges, while challenging assumptions about which patients may benefit most from advanced therapies. Dhatariya highlights that CGM and AID can provide valuable support for individuals who may struggle with traditional insulin management, while also emphasizing the need for appropriate education and follow-up to ensure safe and effective use.The group also discusses CGM use in type 2 diabetes and the growing evidence supporting broader access. Dhatariya explains that adoption has been slower because of the larger population affected by type 2 diabetes but notes emerging data suggesting CGM may help reduce complications, hospitalizations, and long-term healthcare costs. He describes the impact of seeing real-time glucose data, explaining how personal experience with CGM can help people better understand the relationship between food, behavior, and glucose patterns.The conversation then turns to access to GLP-1 receptor agonists in the UK and how healthcare systems determine eligibility for newer therapies. Dhatariya discusses the role of national guidance and health economic evaluations in balancing access, affordability, and sustainability. He highlights how improving obesity-related disease management may have broader benefits, including helping reduce the burden of diabetes, cardiovascular disease, and other chronic conditions.The episode also explores inpatient diabetes care and the increasing presence of diabetes technology in hospital settings. Dhatariya discusses guidance developed by the Joint British Diabetes Societies for Inpatient Care to help clinicians safely manage patients admitted while using CGM, insulin pumps, and AID systems. He emphasizes that devices should not automatically be removed and that patients may be able to continue using technology when they are well enough and capable of managing their systems.Finally, Dhatariya discusses the importance of structured diabetes education, including the DAFNE (Dose Adjustment For Normal Eating) program, which teaches carbohydrate counting, insulin adjustment, and self-management skills. He emphasizes that as diabetes technology becomes more advanced, education remains essential for both patients and clinicians. The episode concludes with a discussion of the need for continued advocacy, specialist care, and equitable access to ensure people with diabetes can benefit from ongoing advances in diabetes technology.Editors' Note: Isaacs reports disclosures with Dexcom, Abbott, Lilly, Novo Nordisk, Medtronic, Insulet, and others. Bellini reports disclosures with Abbott Diabetes Care, MannKind, Povention Bio, and others. Dhatariya reports disclosures with AstraZeneca, Boehringer Ingelheim, Eli Lilly, and Novo Nordisk.

What does it take to go from helping millions of people breathe easier to helping patients keep their legs?   Join The Heart of Innovation as Kym McNicholas talks with Sarvajna Dwivedi, Ph.D., entrepreneur, inventor, and CEO of AngioSafe, whose career has spanned some of the most challenging problems in medicine.   Sarvajna co-founded Pearl Therapeutics, a company focused on breakthrough respiratory therapies that was ultimately acquired by AstraZeneca for $1.15 billion. Along the way, he helped develop inhaled therapies and drug-device combinations designed to improve the lives of patients with asthma and COPD. (AngioSafe United States)   Today, his focus has shifted from the lungs to the arteries.   As CEO and co-founder of AngioSafe, Sarvajna is leading the development of the Santreva-ATK Endovascular Revascularization Catheter, a novel device designed to restore blood flow through some of the most challenging chronic total occlusions (CTOs) physicians encounter in patients with peripheral artery disease (PAD). The technology is designed to cross completely blocked arteries, compress plaque, create a new channel, and restore blood flow without relying on a guidewire or external power source. (Medical Economics)   In this episode, we discuss:   • How a pharmaceutical scientist became a medical device innovator   • The story behind Pearl Therapeutics and its $1.15 billion acquisition   • Why chronic total occlusions remain one of the biggest challenges in PAD treatment   • How AngioSafe's Santreva-ATK technology works   • What it means to restore blood flow through arteries that are 100% blocked   • The future of cardiovascular and vascular innovation   If you or someone you love has peripheral artery disease, diabetes, leg pain while walking, non-healing wounds, or has been told an artery is completely blocked, this is a conversation you won't want to miss.  

Con motivo del  Día Mundial de la Amiloidosis Hereditaria que se celebra el 10 de junio, Marta Moreno, vicepresidenta de Asuntos Corporativos y Acceso al Mercado de AstraZeneca España, ha estado en Fin de Semana de COPE para hablar con Cristina Lopez Schlinting sobre la amiloidosis hereditaria por transtirretina (ATTRv), también conocida como enfermedad de Andrade.En España, esta patología rara, progresiva y multisistémica sigue siendo en gran parte desconocida e infradiagnosticada. Se estima que más de 350 personas conviven actualmente con ella, aunque podría haber más casos sin identificar por la complejidad del diagnóstico . La ATTRv puede afectar a distintos órganos, entre ellos el sistema nervioso y el corazón y presentar síntomas muy variados como hormigueos, pérdida de sensibilidad, fatiga extrema, trastornos gastrointestinales, dificultades motoras o problemas cardiacos, lo que hace que a menudo se confunda con otras enfermedades y se retrase su ...

The Road to Macstock takes a serious turn as Mike T. Rose previews his workshop on becoming a digital caretaker for family members and loved ones. Mike discusses scams targeting older adults, password sharing, remote support, Apple Passwords, financial preparedness, and the need to balance protection, respect, independence, and trust when helping others manage their digital lives.  Today's edition of MacVoices is supported by MacVoices Live!, our weekly live panel discussion of what is going in the Apple space as well as the larger tech world, and how it is impacting you. Join us live at YouTube.com/MacVoicesTV at 8 PM Eastern 5 PM Pacific, or whatever time that is wherever you are and participate in the chat, or catch the edited and segmented versions of the show on the regular MacVoices channels and feeds. Show Notes: Chapters: 00:00 Introduction to Mike T. Rose on the Road to Macstock00:59 Remembering Mike stepping in during a past conference02:12 Mike reflects on filling in and returning to MacStock03:00 Speaker continuity and community expectations04:23 Staying healthy before the conference04:52 Mike introduces his workshop format05:12 Stepping into the role of a digital caretaker06:48 A Microsoft Office upgrade reveals a bigger issue08:39 A family member is caught by a Venmo scam09:19 Managing risks, passwords, and financial access10:11 Using built-in Apple tools instead of advanced services10:25 Safari, Chrome, verification codes, and Apple Passwords10:57 Setting up shared family password folders11:29 Defining digital caretaking12:39 The family “alpha nerd” becomes responsible14:11 Remote tech support challenges and FaceTime troubleshooting16:01 Asynchronous support, screenshots, and remote access tools17:57 Older adults as prime targets for scammers18:53 AARP, Craig Newmark, and scam-interruption resources19:51 Gift cards, retail workers, and scam warning signs20:35 Deepfakes, safe words, and trusted contacts21:40 Fake profiles and stolen valor scams22:48 Protecting family members from criminal targeting23:25 Romance scams, business scams, and phishing tactics25:02 Keeping loved ones safe without burning out26:09 The Beekeeper as a scam-awareness example27:07 Recommended resources and My Mother's Money28:18 Financial preparedness and how quickly gaps appear29:39 Using AI tools to find validated resources30:18 Why this workshop may matter to everyone31:02 The future reversal of helper and helped33:00 Balancing safety, respect, and autonomy34:00 Managing support while preserving dignity36:23 Mike's MacStock discount code37:01 Registering for MacStock and planning ahead38:14 Where to find Mike T. Rose and The Aftershow39:29 Mike's social channels and listener acknowledgments40:17 Remembering John Martellaro and Chuck La Tournous41:22 Final Macstock encouragement and wrap-up Guests: Mike Rose is a past Macstock speaker and multi-year attendee. He is an occasional podcaster with fellow Macstock speaker Kelly Guimont at aftershowpodcast.com, continuing their collaboration from the much-missed TUAW.com (The Unofficial Apple Weblog) in the 2000s and 2010s.Mike began his technology career at the dawn of the desktop publishing revolution, helping transform workflows and introduce the Mac at Entertainment Weekly and LIFE magazines in the 1990s. After his second career in the event production and sales training industry (working with clients such as Pfizer, Dell, AstraZeneca, Johnson & Johnson, and Deloitte), he pivoted to enterprise software in 2013 and is now a Senior Director of Solution Engineering at Salesforce.Outside of work, Mike is active in an NYC community choir, and supports his wife Heidi's congregation as a volunteer technology, AV and operations consultant. Mike & Heidi live in Brooklyn, NY with their two young adult daughters and one young adult cat. Catch him on The Aftershow with Kelly Guimont. Support:      Become a MacVoices Patron on Patreon     http://patreon.com/macvoices      Enjoy this episode? Make a one-time donation with PayPal Connect:      Web:     http://macvoices.com      Twitter:     http://www.twitter.com/chuckjoiner     http://www.twitter.com/macvoices      Mastodon:     https://mastodon.cloud/@chuckjoiner      Facebook:     http://www.facebook.com/chuck.joiner      MacVoices Page on Facebook:     http://www.facebook.com/macvoices/      MacVoices Group on Facebook:     http://www.facebook.com/groups/macvoice      LinkedIn:     https://www.linkedin.com/in/chuckjoiner/      Instagram:     https://www.instagram.com/chuckjoiner/ Subscribe:      Audio in iTunes     Video in iTunes      Subscribe manually via iTunes or any podcatcher:      Audio: http://www.macvoices.com/rss/macvoicesrss      Video: http://www.macvoices.com/rss/macvoicesvideorss

Arun Krishnan, SVP of Global Supply Chain and Strategy at AstraZeneca, shares how the company is reimagining its supply chain to support ambitious growth while keeping patients at the center. He discusses AstraZeneca's focus on innovation, AI-enabled ways of working, self-healing supply chains, and the importance of building capabilities for the future. Arun also explains how the organization continues to maintain strong global supply delivery amid volatility, from the pandemic to geopolitical disruption. Throughout the conversation, he emphasizes the role of curiosity, continuous learning, and empowered leadership in helping people and supply chains adapt to a rapidly changing world.Discover more details here.Follow us on:Instagram: http://bit.ly/2Wba8v7LinkedIn: https://bit.ly/4hbidqoFacebook: http://bit.ly/2HtryLd

As concerns escalate about the deadly Ebola virus outbreak in Africa, we bring you the unique insights of Dr. Peter Piot, a renowned microbiologist who co-discovered the virus 50 years ago during the first recorded outbreak of the disease. His on-the-ground account of that crisis was provided to us in April before the current outbreak was declared, but it contains valuable historical perspective and shares lessons learned that he carried forward in his consequential career.  “What I saw from the beginning is the most important thing is to listen to people and that you need to act fast to save lives, before you have the evidence you would like to have.”    He followed his contributions on Ebola by diving into the fight against HIV/AIDS, eventually reshaping global response in leadership roles at the World Health Organization and United Nations. As he shares with host Lindsey Smith, the learnings in that case were more pragmatic than scientific. “We had to redefine HIV/AIDS not as a medical problem but as an economic and security problem in order to get it on the political agenda.”  Tune in for a fascinating episode that takes you from the gritty frontlines of public health crises to the battles for funding and attention in the halls of power as Dr. Piot shares what it actually takes to move the world to respond effectively to health threats. Mentioned in this episode: London School of Hygiene & Tropical Medicine If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast

The Road to Macstock takes a serious turn as Mike T. Rose previews his workshop on becoming a digital caretaker for family members and loved ones. Mike discusses scams targeting older adults, password sharing, remote support, Apple Passwords, financial preparedness, and the need to balance protection, respect, independence, and trust when helping others manage their digital lives.  Today's edition of MacVoices is supported by MacVoices Live!, our weekly live panel discussion of what is going in the Apple space as well as the larger tech world, and how it is impacting you. Join us live at YouTube.com/MacVoicesTV at 8 PM Eastern 5 PM Pacific, or whatever time that is wherever you are and participate in the chat, or catch the edited and segmented versions of the show on the regular MacVoices channels and feeds. Show Notes: Chapters: 00:00 Introduction to Mike T. Rose on the Road to Macstock 00:59 Remembering Mike stepping in during a past conference 02:12 Mike reflects on filling in and returning to MacStock 03:00 Speaker continuity and community expectations 04:23 Staying healthy before the conference 04:52 Mike introduces his workshop format 05:12 Stepping into the role of a digital caretaker 06:48 A Microsoft Office upgrade reveals a bigger issue 08:39 A family member is caught by a Venmo scam 09:19 Managing risks, passwords, and financial access 10:11 Using built-in Apple tools instead of advanced services 10:25 Safari, Chrome, verification codes, and Apple Passwords 10:57 Setting up shared family password folders 11:29 Defining digital caretaking 12:39 The family "alpha nerd" becomes responsible 14:11 Remote tech support challenges and FaceTime troubleshooting 16:01 Asynchronous support, screenshots, and remote access tools 17:57 Older adults as prime targets for scammers 18:53 AARP, Craig Newmark, and scam-interruption resources 19:51 Gift cards, retail workers, and scam warning signs 20:35 Deepfakes, safe words, and trusted contacts 21:40 Fake profiles and stolen valor scams 22:48 Protecting family members from criminal targeting 23:25 Romance scams, business scams, and phishing tactics 25:02 Keeping loved ones safe without burning out 26:09 The Beekeeper as a scam-awareness example 27:07 Recommended resources and My Mother's Money 28:18 Financial preparedness and how quickly gaps appear 29:39 Using AI tools to find validated resources 30:18 Why this workshop may matter to everyone 31:02 The future reversal of helper and helped 33:00 Balancing safety, respect, and autonomy 34:00 Managing support while preserving dignity 36:23 Mike's MacStock discount code 37:01 Registering for MacStock and planning ahead 38:14 Where to find Mike T. Rose and The Aftershow 39:29 Mike's social channels and listener acknowledgments 40:17 Remembering John Martellaro and Chuck La Tournous 41:22 Final Macstock encouragement and wrap-up Guests: Mike Rose is a past Macstock speaker and multi-year attendee. He is an occasional podcaster with fellow Macstock speaker Kelly Guimont at aftershowpodcast.com, continuing their collaboration from the much-missed TUAW.com (The Unofficial Apple Weblog) in the 2000s and 2010s. Mike began his technology career at the dawn of the desktop publishing revolution, helping transform workflows and introduce the Mac at Entertainment Weekly and LIFE magazines in the 1990s. After his second career in the event production and sales training industry (working with clients such as Pfizer, Dell, AstraZeneca, Johnson & Johnson, and Deloitte), he pivoted to enterprise software in 2013 and is now a Senior Director of Solution Engineering at Salesforce. Outside of work, Mike is active in an NYC community choir, and supports his wife Heidi's congregation as a volunteer technology, AV and operations consultant. Mike & Heidi live in Brooklyn, NY with their two young adult daughters and one young adult cat. Catch him on The Aftershow with Kelly Guimont. Support:      Become a MacVoices Patron on Patreon      http://patreon.com/macvoices      Enjoy this episode? Make a one-time donation with PayPal Connect:      Web:      http://macvoices.com      Twitter:      http://www.twitter.com/chuckjoiner      http://www.twitter.com/macvoices      Mastodon:      https://mastodon.cloud/@chuckjoiner      Facebook:      http://www.facebook.com/chuck.joiner      MacVoices Page on Facebook:      http://www.facebook.com/macvoices/      MacVoices Group on Facebook:      http://www.facebook.com/groups/macvoice      LinkedIn:      https://www.linkedin.com/in/chuckjoiner/      Instagram:      https://www.instagram.com/chuckjoiner/ Subscribe:      Audio in iTunes      Video in iTunes      Subscribe manually via iTunes or any podcatcher:      Audio: http://www.macvoices.com/rss/macvoicesrss      Video: http://www.macvoices.com/rss/macvoicesvideorss

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/CC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/VCW865. CME/MOC/CC/AAPA/IPCE credit will be available until June 19, 2027.The Immunotherapy Playbook for Resectable NSCLC: Real-World Challenges and Practical Strategies In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through independent educational grants from AstraZeneca, Bristol Myers Squibb, and Merck & Co., Inc., Rahway, NJ, USA.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/CC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/VCW865. CME/MOC/CC/AAPA/IPCE credit will be available until June 19, 2027.The Immunotherapy Playbook for Resectable NSCLC: Real-World Challenges and Practical Strategies In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through independent educational grants from AstraZeneca, Bristol Myers Squibb, and Merck & Co., Inc., Rahway, NJ, USA.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/CC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/VCW865. CME/MOC/CC/AAPA/IPCE credit will be available until June 19, 2027.The Immunotherapy Playbook for Resectable NSCLC: Real-World Challenges and Practical Strategies In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through independent educational grants from AstraZeneca, Bristol Myers Squibb, and Merck & Co., Inc., Rahway, NJ, USA.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/CC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/VCW865. CME/MOC/CC/AAPA/IPCE credit will be available until June 19, 2027.The Immunotherapy Playbook for Resectable NSCLC: Real-World Challenges and Practical Strategies In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through independent educational grants from AstraZeneca, Bristol Myers Squibb, and Merck & Co., Inc., Rahway, NJ, USA.Disclosure information is available at the beginning of the video presentation.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a range of fascinating advancements in the industry, each with significant implications for future patient care and drug development. At the recent American Society of Clinical Oncology (ASCO) 2026 conference, Akeso's ivonescimab, a pioneering PD-1xVEGF bispecific antibody, demonstrated a 34% reduction in death risk when combined with chemotherapy for first-line lung cancer treatment. This marks a pivotal moment in cancer therapeutics, illustrating how bispecific antibodies can enhance treatment efficacy. The evolving landscape of cancer treatment continues to highlight the importance of these innovative approaches. Johnson & Johnson's Erleada has shown promising results in prostate cancer, achieving positive outcomes in its Phase 3 Proteus study. The trial emphasized the efficacy of Erleada when administered perioperatively to prostate cancer patients, indicating a shift towards more personalized and comprehensive care that incorporates targeted therapies before and after surgery. In another significant breakthrough, Lilly's Retemvo exhibited dramatic results in early-stage lung cancer with RET fusion-positive markers, reducing disease progression or death by 83% as adjuvant therapy. This underscores the critical role of molecularly targeted therapies for patients with specific genetic profiles, offering hope for improved survival outcomes. On the frontlines of infectious diseases, Shionogi's COVID-19 antiviral Xocova has received FDA approval as a post-exposure prophylactic. This milestone highlights the challenging yet dynamic landscape of antiviral drug development, offering a new tool in managing COVID-19 exposures after previous challenges in demonstrating effectiveness as a treatment. MannKind's inhaled insulin, Afrezza, has been approved for pediatric use. This approval could rejuvenate its market presence by providing a more convenient insulin delivery system aimed at improving adherence and glycemic control among younger patients. In oncology news, Pfizer's Talzenna combination therapy received broader FDA approval for castration-sensitive prostate cancer. This positions it as a competitive option against Johnson & Johnson's PARP inhibitor combination therapy. Additionally, AstraZeneca's Imfinzi and Imjudo combination showed promise in early-stage liver cancer by reducing disease progression risks by 30%, broadening immunotherapy applications. The market dynamics are also shifting with significant strategic movements like Eli Lilly's acquisition of Kelonia Therapeutics for $3.2 billion. This decision is driven by promising in vivo CAR-T data demonstrating unprecedented response rates and reflects the increasing importance of innovative CAR-T therapies in oncology. Eli Lilly's Kelonia Therapeutics' cell therapy showcased an impressive 100% response rate in a Phase 1 trial for relapsed or refractory multiple myeloma. This CAR-T therapy targets the BCMA antigen and could revolutionize treatment paradigms by offering more effective responses. Meanwhile, Pfizer's transformative research on RAS inhibitors holds potential to redefine treatment paradigms in pancreatic cancer—a notoriously difficult-to-treat type due to its complex biology. Revolution Medicines aims to maintain its leadership within this space amidst growing competition. Revolution Medicines also reported compelling results with their KRAS inhibitor, which nearly doubles survival rates for metastatic pancreatic cancer patients harboring KRAS mutations. Given the historically poor prognosis associated with pancreatic cancer, these findings represent a significant advancement in managing this aggressive type. In ovarian cancer research, Gilead's TUB-040 demonstrated a 61% tumor response rate for platinum-resistant ovarian cancer in a Phase 1 trial. This highlights the potential of antibody-drug conjugates (ADCs) to overcome resistance mechanisms and improve outcomes in difficult-to-treat cancers. Regulatory updates include Johnson & Johnson receiving FDA label expansion for Tremfya to inhibit structural joint damage in active psoriatic arthritis patients. This expansion provides broader treatment options for patients suffering from debilitating conditions by reinforcing the role of IL-23 inhibitors in autoimmune disease management. Strategic partnerships are also shaping drug development's future landscape. Notably, Servier's acquisition of Edgewise Therapeutics' muscular dystrophy unit underscores growing focus on rare diseases and neuromuscular disorders. Eli Lilly's agreements with Haisco Pharmaceutical and Hanmi Pharm reflect ongoing R&D investments aimed at expanding therapeutic portfolios across various indications. These developments illustrate a broader trend toward personalized medicine and targeted therapies that enhance treatment efficacy by leveraging specific genetic or molecular characteristics. Despite advancements, challenges remain as exemplified by Oculis' OCS-01 failing Phase 3 trials for diabetic macular edema—highlighting inherent risks in drug development. Overall, these updates underscore significant scientific progress and promise improvements in patient outcomes through novel therapeutic approaches and collaborative efforts within this vibrant industry landscape.Support the show

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we'll explore a landscape teeming with strategic partnerships, groundbreaking clinical trial results, regulatory shifts, and innovative therapeutic approaches that are redefining patient care and drug development. Pfizer's monumental $10 billion collaboration with Innovent Biologics stands out as a testament to the shifting dynamics of the oncology sector. This partnership aims to develop 12 antibody-drug conjugate (ADC) and multispecific antibody programs, spotlighting these therapies' growing significance in oncology. The precision of antibodies in delivering cytotoxic agents directly to cancer cells offers a new frontier in minimizing collateral damage to healthy tissues—a crucial advancement in cancer treatment. The deal not only highlights Pfizer's commitment to expanding its oncology pipeline but also underscores the strategic importance of leveraging China's accelerated drug development ecosystem. In regulatory news, AstraZeneca's Imfinzi has garnered FDA approval for BCG-naive high-risk non-muscle-invasive bladder cancer. This milestone for PD-L1 inhibitors reflects the evolving landscape of immunotherapy. By harnessing monoclonal antibodies in combination therapies, the potential for enhanced anticancer efficacy is significant. With few therapeutic alternatives available, this approval presents a lifeline for many bladder cancer patients. Clinical trial outcomes also continue to capture attention. Eli Lilly's Nectin-4 targeting ADC showed promising results in advanced urothelial cancer, positioning itself as a potential competitor to Padcev. This innovation in ADC technology demonstrates the industry's relentless pursuit of targeted therapies that can revolutionize treatment paradigms. Bristol Myers Squibb's mezigdomide offers another example by showing a 52% reduction in progression risk for relapsed or refractory multiple myeloma patients, emphasizing the focus on addressing specific molecular pathways. In the realm of bispecific antibodies, Phanes Therapeutics' CLDN18.2/CD47 targeting therapy reported encouraging Phase 2 results in metastatic pancreatic ductal adenocarcinoma. These antibodies' ability to simultaneously engage multiple targets enhances their therapeutic efficacy against stubborn cancers, broadening the horizon for treatment possibilities. Meanwhile, Replimune's resubmission of its RP1 melanoma Biologics License Application (BLA) highlights the intricate dance between drug development and regulatory processes amid organizational shifts at the FDA. Such efforts reflect the continual adaptation required within the industry to navigate complex regulatory landscapes. On the funding front, Psilera's successful $8.8 million seed round indicates growing interest in psychedelic therapies for neurological conditions. Similarly, Reprogram Biosciences raised $6 million for its AI-driven cell reprogramming oncology platform, illustrating how artificial intelligence is becoming integral to advancing drug discovery and development. However, not all updates were positive. Agios Pharmaceuticals faced setbacks as their pyruvate kinase activator failed a Phase 2b trial for lower-risk myelodysplastic syndromes, serving as a sobering reminder of the inherent risks involved in drug development. Dizal Pharma emerges as a beacon of hope in lung cancer treatment following Takeda's EGFR exon 20 drug setback. By challenging existing treatments with promising small molecule data, Dizal exemplifies precision medicine's role in redefining oncology protocols—offering personalized patient options that could set new standards in treatment efficacy. The issue of drug pricing remains contentious, particularly highlighted by an AARP analysis showing an 81% increase post-launch prices stateside compared to a 13% decrease abroad. This disparity raises critical questions about achieving equitable access across markets amid Medicare negotiations and global pricing strategies like "most favored nation" policies. Regulatory updates continue with Johnson & Johnson's Tremfya label expansion stateside and AbbVie's EU extension for Venclyxto—moves that reflect efforts to maximize therapeutic reach and commercial viability across diverse geographies. Finally, Gilead Sciences' decision to discontinue its lead rheumatoid arthritis drug from MiroBio underscores ongoing challenges within emerging fields like BTLA agonists—a reminder of both innovation's promise and its perilous nature when faced with unproven therapeutic avenues. As these varied developments unfold, they collectively signal an era characterized by rapid scientific innovation and strategic collaborations across geographies alongside evolving regulatory landscapes—all driving towards enhanced patient care through more effective treatments globally. This concludes today's insights from Pharma Daily—a world where dynamic change continues reshaping healthcare delivery standards towards unprecedented possibilities for patient outcomes worldwide. Thank you for joining us; stay tuned for more updates on tomorrow's horizon-shaping advancements.Support the show

What happens when a successful oncologist leaves clinical practice to help develop cancer treatments on a global scale? In this episode of The Lebanese Physicians Podcast, Dr. Safi Shahda shares his journey from academic oncology to leadership roles at Eli Lilly, Intellia Therapeutics, and AstraZeneca. We discuss career transitions, pharma misconceptions, innovation, AI in drug development, mentorship, and how physicians can expand their impact beyond the bedside. #LebanesePhysiciansPodcast #PharmaCareers #Oncology #ClinicalResearch #DrugDevelopment #MedicalLeadership #PhysicianCareer #AstraZeneca #Biotech #HealthcareInnovation #ArtificialIntelligence #CancerResearch #MedicalEducation #CareerGrowth #PhysicianLife #Medicine #Subscribe #Podcast #Healthcare #clinicaltrials ⁨@thelebanesephysicianspodcast⁩   ⁨@astrazeneca⁩  On all podcast apps Website: https://thelebanesephysicianspodcast.podbean.com

AstraZeneca (AZN) is aiming to redefine cancer care by shifting the focus from late-stage interventions to early-line precision medicine. Dave Fredrickson, EVP of Oncology Business at AstraZeneca, discusses the company's aggressive strategy to replace traditional chemotherapy with targeted treatments that minimize side effects. Looking ahead, the conversation highlights recent regulatory milestones and the transformative potential of cell therapy to dramatically improve patient outcomes.======== Schwab Network ========Empowering every investor and trader, every market day.Subscribe to the Market Minute newsletter - https://schwabnetwork.com/subscribeDownload the iOS app - https://apps.apple.com/us/app/schwab-network/id1460719185Download the Amazon Fire Tv App - https://www.amazon.com/TD-Ameritrade-Network/dp/B07KRD76C7Watch on Sling - https://watch.sling.com/1/asset/191928615bd8d47686f94682aefaa007/watchWatch on Vizio - https://www.vizio.com/en/watchfreeplus-exploreWatch on DistroTV - https://www.distro.tv/live/schwab-network/Follow us on X – https://twitter.com/schwabnetworkFollow us on Facebook – https://www.facebook.com/schwabnetworkFollow us on LinkedIn - https://www.linkedin.com/company/schwab-network/About Schwab Network - https://schwabnetwork.com/about

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/QKH865. CME/MOC/AAPA credit will be available until May 13, 2027.Expanding Bispecific Options for Acute Lymphoblastic Leukemia: From Current Standards to Future Practice In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/QKH865. CME/MOC/AAPA credit will be available until May 13, 2027.Expanding Bispecific Options for Acute Lymphoblastic Leukemia: From Current Standards to Future Practice In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/QKH865. CME/MOC/AAPA credit will be available until May 13, 2027.Expanding Bispecific Options for Acute Lymphoblastic Leukemia: From Current Standards to Future Practice In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/QKH865. CME/MOC/AAPA credit will be available until May 13, 2027.Expanding Bispecific Options for Acute Lymphoblastic Leukemia: From Current Standards to Future Practice In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/QKH865. CME/MOC/AAPA credit will be available until May 13, 2027.Expanding Bispecific Options for Acute Lymphoblastic Leukemia: From Current Standards to Future Practice In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/QKH865. CME/MOC/AAPA credit will be available until May 13, 2027.Expanding Bispecific Options for Acute Lymphoblastic Leukemia: From Current Standards to Future Practice In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/QKH865. CME/MOC/AAPA credit will be available until May 13, 2027.Expanding Bispecific Options for Acute Lymphoblastic Leukemia: From Current Standards to Future Practice In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure information is available at the beginning of the video presentation.

This episode covers: Cardiology This Week: A concise summary of recent studies The heart in high altitude Mitral annular disjunction Mythbusters: Weekend mortality Host: Rick Grobbee Guests: JP Carpenter, Kristina Haugaa, Silvia Ulrich Want to watch that episode? Go to: https://esc365.escardio.org/event/2563 Want to watch that extended interview on mitral annular disjonction, go to: https://esc365.escardio.org/event/2563?resource=interview   Disclaimer ESC TV Today is supported by Novartis through an independent funding. The programme has not been influenced in any way by its funding partner. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. All declarations of interest are listed at the end of the episode. The ESC is not liable for any translated content of this video. The English language always prevails. ESC TV Today uses a range of tools and resources (including AI) to support content production. All content is reviewed and approved by the editorial team. Statements and opinions expressed by guest speakers are their own.   Declarations of interests Stephan Achenbach, Yasmina Bououdina, Rick Grobbee, Kristina Haugaa, Nicolle Kraenkel and Silvia Ulrich have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Novo Nordisk, Pfizer, Sanofi, Servier, Takeda, Tecnimede, Viatris. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder MyCardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Abbott Vascular, Bristol Myers Squibb, Daiichi Sankyo, Edwards Lifesciences, Novo Nordisk, Sanofi Aventis, Terumo. David Duncker has declared to have potential conflicts of interest to report: lecture honoraria from Abbott, Astra Zeneca, Biotronik, Boehringer Ingelheim, Boston Scientifics, Bristol Meyers Squibb, CVRx, Daiichi Sankyo, Medtronic, Microport, Pfizer, Sanofi, Zoll. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Felix Mahfoud has declared to have potential conflicts of interest to report: research grants from Deutsche Forschungsgemeinschaft (SFB TRR219), Deutsche Gesellschaft für Kardiologie (DGK), Deutsche Herzstiftung, Ablative Solutions, ReCor Medical. Consulting fees, payment honoraria lectures, presentations, speaker, support travel costs: Ablative Solutions, Astra-Zeneca, Novartis, Inari, Recor Medical, Medtronic, Philips, Merck. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada.  Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

Host: Rick Grobbee Guest: Kristina Haugaa Want to watch that extended interview on https://esc365.escardio.org/event/2563?resource=interview Go to: Want to watch that episode? Go to: https://esc365.escardio.org/event/2563   Disclaimer ESC TV Today is supported by Novartis through an independent funding. The programme has not been influenced in any way by its funding partner. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. All declarations of interest are listed at the end of the episode. The ESC is not liable for any translated content of this video. The English language always prevails. ESC TV Today uses a range of tools and resources (including AI) to support content production. All content is reviewed and approved by the editorial team. Statements and opinions expressed by guest speakers are their own.   Declarations of interests Stephan Achenbach, Yasmina Bououdina, Rick Grobbee, Kristina Haugaa and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Novo Nordisk, Pfizer, Sanofi, Servier, Takeda, Tecnimede, Viatris. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder MyCardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Abbott Vascular, Bristol Myers Squibb, Daiichi Sankyo, Edwards Lifesciences, Novo Nordisk, Sanofi Aventis, Terumo. David Duncker has declared to have potential conflicts of interest to report: lecture honoraria from Abbott, Astra Zeneca, Biotronik, Boehringer Ingelheim, Boston Scientifics, Bristol Meyers Squibb, CVRx, Daiichi Sankyo, Medtronic, Microport, Pfizer, Sanofi, Zoll. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Felix Mahfoud has declared to have potential conflicts of interest to report: research grants from Deutsche Forschungsgemeinschaft (SFB TRR219), Deutsche Gesellschaft für Kardiologie (DGK), Deutsche Herzstiftung, Ablative Solutions, ReCor Medical. Consulting fees, payment honoraria lectures, presentations, speaker, support travel costs: Ablative Solutions, Astra-Zeneca, Novartis, Inari, Recor Medical, Medtronic, Philips, Merck. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

Welcome to IDEA Collider. In this episode, host Alex Gray is joined by IDEA Pharma colleagues David Radwaner and Tom Brockbank to dissect the history, strategy, and future of immuno-oncology (IO). The trio explores how PD-1 and PD-L1 therapies revolutionized cancer treatment, acting as a brake on the immune system to offer unprecedented durability and long-term survival for patients.  They take a deep dive into the fascinating commercial and clinical race between Merck's Keytruda and BMS's Opdivo. Learn how Merck's strategic decisions—including smart statistical trial designs, targeted biomarker approaches in first-line non-small cell lung cancer, and tumor-agnostic labels like MSI-high—allowed Keytruda to secure market dominance. Finally, Alex, David, and Tom look ahead to the next ten years, discussing whether emerging players like AstraZeneca and China's Akeso / Summit will displace Keytruda, or if the future lies in combination therapies.    Episode Timestamps:  00:00:00 - Introduction: Meet David Radwaner, Tom Brockbank, and host Alex Gray.  00:01:45 - The Origins of IO: The Nobel Prize-winning discovery of PD-1 and CTLA-4 checkpoints.  00:03:55 - Why PD-1 / PD-L1 Won: The unique breadth of utility and unparalleled durability of long-term survival.  00:06:21 - Keytruda vs. Opdivo: How Merck's strategic trial design and smart statistical work outpaced BMS's early lead.  00:11:48 - The NSCLC Inflection Point: Why narrowing the patient population (PD-L1 - 50%) cemented Keytruda's foundation in first-line lung cancer.  00:14:20 - Tumor-Agnostic Success: Merck's bold move into MSI-high and broad biomarker-led strategies.  00:16:09 - Science or Luck? Analyzing Merck's aggressive and risky clinical development strategy.  00:18:00 - The Next 10 Years: Will anyone displace Keytruda? Assessing the future strategies of Merck, BMS, AstraZeneca, and Akeso/Summit    Don't forget to Like, Share, Subscribe, Rate, and Review!   Keep up with Alex Gray;  LinkedIn: https://www.linkedin.com/in/alexander-gray-934a653/    Keep up with David Radwaner;  LinkedIn: https://www.linkedin.com/in/david-radwaner-1b496343/    Keep up with Tom Brockbank;  LinkedIn: https://www.linkedin.com/in/tom-brockbank-159bb4116/      Follow IDEA Pharma On; Website: https://www.ideapharma.com/    Listen to more fantastic podcast episodes: https://ideacollider.simplecast.com/

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a myriad of events shaping the industry, ranging from regulatory hurdles to strategic acquisitions and scientific breakthroughs. A significant milestone has been achieved by Outlook Therapeutics with its product Lytenava (bevacizumab), which recently won an appeal with the FDA for wet age-related macular degeneration treatment. This antibody therapy, aimed at VEGF inhibitors, marks a notable advancement in ophthalmology, potentially transforming management strategies for this debilitating condition. Monoclonal antibodies like Lytenava continue to underscore their importance in treating chronic diseases, offering hope for patients and setting benchmarks for similar therapeutic innovations. On a less favorable note, AstraZeneca encountered a setback when their breast cancer treatment camizestrant faced rejection from an FDA advisory committee. Despite robust phase 3 data for hormone receptor-positive breast cancer, the advisory committee's decision delays the drug's review process. This serves as a stark reminder of the stringent requirements oncology treatments must meet and highlights the critical need for comprehensive clinical data to ensure patient safety and drug efficacy in this competitive field. Amidst these developments, Astellas is proactively addressing upcoming patent expirations, particularly for Xtandi in 2026. The company has announced a five-year growth strategy focused on pipeline acquisitions, illustrating broader industry trends where diversifying portfolios through acquisitions and partnerships is crucial for maintaining competitiveness and delivering innovative therapies. Business development activities continue to be a highlight within the sector. Apogee Therapeutics and Blackstone Life Sciences have entered into a $1.3 billion royalty financing agreement to advance an eczema drug, underscoring ongoing investments in autoimmune treatments. Similarly, AGC Biologics' partnership with Teikoku Seiyaku on microbial CDMO services aims at advancing musculoskeletal therapies, showcasing how collaborations can leverage specialized manufacturing capabilities for therapeutic progress. Clinical trials also made headlines as Junshi Biosciences reported that its drug toripalimab met primary endpoints in phase 3 trials for non-small cell lung cancer perioperative treatment. This achievement underscores the growing influence of immunotherapies in oncology, promising improved surgical outcomes and enhancing their role within cancer treatment paradigms. Funding continues to play a pivotal role in sustaining innovation within the industry. Editas Medicine recently raised $125 million to propel its CRISPR-based gene therapy pipeline forward. Such financial backing is instrumental in transitioning promising therapies from preclinical stages to market readiness, ensuring that groundbreaking science translates into patient-accessible treatments. Regulatory landscapes remain dynamic, with ongoing discussions about updating COVID-19 vaccine formulations to target emerging subvariants. The FDA's commitment to adapting vaccine guidelines reflects a proactive stance in infectious disease management, crucial for maintaining vaccine efficacy against evolving pathogens. In acquisition news, Olympus' purchase of Bioprotect for $270 million adds biodegradable balloon spacer technology to its prostate cancer radiation therapy offerings. This acquisition highlights how medical device innovations can complement pharmaceutical approaches, enhancing treatment efficacy and patient quality of life. These developments collectively paint a vibrant picture of the biotech and pharmaceutical industries—a landscape where scientific advancements, regulatory challenges, strategic planning, and financial investments converge. The implications are far-reaching, potentially redefining treatment paradigms across various therapeutic areas as these sectors continue their pursuit of innovation and improved patient care outcomes. Navigating this landscape also involves addressing broader challenges such as policy shifts and pricing pressures within key markets like the United States. Companies must remain adaptable, balancing growth strategies with compliance demands amidst changing regulatory environments—a theme echoed by recent surveys indicating heightened pressure on healthcare firms to maintain profitability. Moreover, geopolitical considerations are influencing cross-border investments in biotechnology as policymakers debate strategies best suited for managing foreign influence—reflecting broader concerns about national security and economic competitiveness within this critical sector. As we continue monitoring these dynamic shifts within pharmaceuticals and biotechnology, it's evident that scientific innovation remains tightly interwoven with regulatory scrutiny and financial dynamics. The ongoing dance between these elements will undoubtedly shape future trajectories in healthcare advancements globally, promising new horizons in patient care while addressing pressing health challenges worldwide. That's all for today's episode of Pharma Daily—where we keep you informed on the latest developments driving progress within pharmaceuticals and biotechnology. Thank you for tuning in; until next time!Support the show

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. The landscape of these industries continues to evolve with significant scientific advancements, regulatory breakthroughs, and strategic maneuvers that are reshaping drug development and patient care. One of the noteworthy developments is the U.S. FDA's recent approval of Gilead Sciences' Hepcludex (bulevirtide) for hepatitis D. This approval marks a comeback for Gilead after previous setbacks due to manufacturing and delivery issues, highlighting the critical importance of addressing regulatory feedback. It's a testament to persistence in overcoming manufacturing challenges to ensure vital therapies reach those in need. This approval signifies a milestone as it's the first FDA-approved therapy targeting chronic hepatitis D virus infection—a niche condition with limited treatment options. Similarly, Pfizer's Braftovi (encorafenib) is expanding its global reach beyond U.S. borders with regulatory approvals in the EU and Canada for colorectal cancer treatment. This broadening geographic footprint reflects a broader industry trend where companies aim to maximize the therapeutic impact of oncology drugs across diverse patient populations. Meanwhile, Astellas Pharma is navigating the looming patent cliff for its prostate cancer drug Xtandi by actively pursuing new licensing deals and implementing cost-cutting measures. This dual approach underscores a widespread industry strategy where companies balance acquisitions with operational efficiency to sustain growth. In the radiopharmaceutical sector, there's notable activity with Lantheus Holdings possibly being acquired by Curium for $7 billion. This potential deal underscores growing interest in radiopharmaceuticals due to their precision in targeting specific cancer types. Complementing this is Niowave's $75 million investment in a radiopharmaceutical isotope plant in Michigan, set to produce actinium-225 by 2028—an isotope crucial for targeted cancer therapies. Regulatory landscapes are also in flux with continued reforms at the FDA despite leadership changes. Initiatives like the Commissioner's National Priority Voucher program illustrate regulatory bodies' commitment to streamlining drug approvals and fostering innovation. On an international note, SK Bioscience is partnering with Colombia to locally produce the chickenpox vaccine Skyvaricella, enhancing vaccine accessibility through technology transfer. Similarly, Eli Lilly's acquisition spree in infectious disease research signals a robust push toward expanding its R&D pipeline for viral and bacterial pathogens. Eli Lilly has announced plans to acquire Curevo, Limmatech Biologics, and another vaccine company for up to $3.8 billion. This strategic acquisition underscores a commitment to enhancing capabilities in infectious diseases—a field that has gained focus post-COVID-19 pandemic. By integrating these companies, Eli Lilly aims to leverage their platforms and expertise for advanced therapeutic solutions against infectious diseases. In gene editing, Eli Lilly is preparing for a Phase 2 trial of a lipid-lowering gene editor from Verve Therapeutics, showing promising cholesterol reductions akin to PCSK9 inhibitors. This highlights gene editing's potential in addressing cardiovascular diseases. A significant development from Lilly's pipeline includes promising results from their base editor technology acquired through Verve Therapeutics—an exciting breakthrough suggesting substantial potential for gene-editing technologies addressing genetic disorders like high cholesterol. In oncology, AstraZeneca and Daiichi Sankyo's Datroway gained FDA approval for triple-negative breast cancer as a first-line treatment. This antibody-drug conjugate targets Trop2, demonstrating the potential of targeted therapy in difficult-to-treat cancers. Kura Oncology's combination therapy featuring darlifarnib and Krazati showed up to a 69% response rate in KRAS G12C-mutated solid tumors during Phase 1 trials, emphasizing precision medicine's potential in targeting specific genetic mutations driving cancer progression. In obesity management, Eli Lilly's retatrutide achieved Phase 3 success with bariatric surgery-like outcomes. The drug acts as a triple hormone receptor agonist, showcasing advancements in metabolic therapies targeting obesity—a condition linked with numerous comorbidities. Moderna's mFlusiva is poised for an FDA advisory committee review as an influenza preventative for older adults—an extension of Moderna's mRNA technology initially used against COVID-19. Collectively, these developments highlight an industry leveraging cutting-edge science and technology to tackle complex medical challenges. As pharmaceutical giants like Eli Lilly consolidate their positions through acquisitions and research collaborations, transformative advancements promise to reshape patient care across various therapeutic areas. These initiatives not only reflect the industry's dynamic nature but also its pivotal role in addressing unmet medical needs worldwide. Eli Lilly's recent strategic acquisitions underscore its commitment to advancing pharmaceutical innovations, particularly in vaccines and cholesterol management sectors. Acquiring three vaccine-focused biotech firms signifies substantial investment in expanding its vaccine portfolio—a move aligned with global immunization strategies. This follows hiring Peter Marks from the FDA, indicating a strategic focus on bolstering expertise within the vaccine domain. The company has been recognized by IDEA Pharma as a leader in pharmaceutical innovation—a testament to its robust pipeline and successful integration of scientific advancements into marketable therapies. Across oncology landscapes highlighted at ASCO conferences are exciting potentials like Summit Therapeutics and Akeso's potential Keytruda rivals that could reshape cancer treatment paradigms if proven effective. As pharmaceutical landscapes continue evolving rapidly through scientific strides tempered by regulatory hurdles—the current environment promises significant advancements offering new hope while demanding strategic agility within healthcare sectors globally.Support the show

The ongoing outbreak of hantavirus infections that originated with passengers on the Dutch cruise ship MV Hondius in April has generated concerns across the globe. This very rare occurrence has led to a number of deaths, required quarantining of passengers and prompted emergency responses from public health authorities in multiple countries.  On this episode of Raise the Line from Elsevier, we're tapping the expertise of a leading authority on the subject, Dr. Jamie Childs of Yale University, to provide you with a scientific understanding of hantaviruses and what level of threat is posed by this situation. In short, Dr. Childs believes this is not the start of a pandemic. “The Andes variant involved here is one of the most dangerous hantaviruses, but it is totally controllable with contact tracing.” This timely conversation with host Lindsey Smith is informed by Dr. Childs' decades of hantavirus research as well as learnings from his role leading the CDC's environmental investigation during the landmark 1993 hantavirus outbreak in the Four Corners region of the American Southwest. And be sure to stay tuned to hear his concerns about the factors complicating containment of the current Ebola outbreak in East Africa. Note: this conversation was recorded on May 19th, 2026. Mentioned in this episode: Yale School of Public Health Yale Institute for Global Health If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast

In the first episode of this series on Obesity, our host is joined by Dr. Mikhail Kosiborod to discuss the evolving science and cardiometabolic diseases associated with obesity. This special episode is sponsored with support from AstraZeneca. Presented by: Neil Skolnik, MD, Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health Mikhail Kosiborod, MD, Senior Vice President Late-Stage Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D at AstraZeneca. Selected references: Cardiovascular-Kidney-Metabolic Health: A Presidential Advisory From the American Heart Association. Circulation October 2023

In this outrageous episode of BS Free MD, Drs. May and Tim Hindmarsh dive headfirst into one of the most absurd headlines they've ever covered: a man attempting to pull a 2-ton police car with his penis… while on fire… all in the name of prostate cancer awareness. But the chaos doesn't stop there. The conversation spirals into pharmaceutical “awareness” campaigns, toxic chemical exposure in artists, questionable modern healthcare practices, pig semen-based cancer research, and the growing tendency of medicine to mask symptoms instead of asking why disease is happening in the first place. Along the way, the hosts mix sharp medical insight with dark humor, personal stories, cocktails, and the kind of unfiltered commentary that's become signature BS Free MD. In This Episode A strongman pulls a police car with his penis while on fire “High Potassium Awareness Day” and pharma-driven health campaigns AstraZeneca's role in disease awareness marketing Why “awareness culture” may actually be advertising Artist Govinder Nazra's tragic death linked to solvent exposure Van Gogh, lead poisoning, and toxic art materials Modern medicine's obsession with symptom masking Screening questionnaires and healthcare bureaucracy Experimental eye drops made from pig semen exosomes Why pigs are used so heavily in medicine and research Alcohol-free beer, bourbon, and Loaded Cannon Distillery Updates on BS Free MD's Substack and upcoming content About BS Free MD BS Free MD explores medicine, culture, relationships, freedom, health, and current events through candid conversations that challenge mainstream narratives. Hosted by physician couple Drs. May and Tim Hindmarsh, the show blends humor, skepticism, storytelling, and medical insight in a way that keeps listeners informed — and entertained. Links & Resources BS Free MD Website BS Free MD Substack BS Free MD on Rumble Athletic Brewing Company

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a series of noteworthy advancements and challenges that are shifting the landscape of drug development and patient care. Starting with AstraZeneca and Daiichi Sankyo, their Trop2-directed antibody-drug conjugate, Datroway, has secured FDA approval for first-line treatment in triple-negative breast cancer. This form of cancer is notoriously aggressive and offers limited treatment options, making this approval a significant milestone. It positions Datroway as a key player in the ADC market targeting TNBC, highlighting the increasing role of antibody-drug conjugates in oncology. This advancement not only expands therapeutic options for patients but also emphasizes the growing importance of ADCs in effectively targeting cancer cells while sparing healthy tissues. In another exciting development, Merck and Kelun Biotech have reported on their SAC-TMT ADC, which when paired with Keytruda, shows a profound impact on PD-L1-positive non-small cell lung cancer patients. Their combination therapy demonstrated a remarkable 65% reduction in disease progression or death compared to Keytruda alone. Presented at the ASCO annual meeting, these findings could potentially revolutionize first-line treatments for NSCLC, further underscoring the promising therapeutic potential of combining ADCs with immunotherapies. However, AstraZeneca faced a setback with a novel breast cancer drug as an FDA advisory committee recommended against its approval. Interestingly, the European Medicines Agency provided a favorable opinion, illustrating the divergent regulatory landscapes across continents. Such discrepancies highlight the complex regulatory environment pharmaceutical companies must navigate and could influence strategic decisions regarding market focus. On the legal front, Eli Lilly is embroiled in controversy over an alleged $200 million rebate fraud scheme involving its diabetes drug, Trulicity. This situation sheds light on ongoing issues within pharmaceutical distribution channels and raises questions about compliance and oversight mechanisms necessary to prevent such financial misconduct. Meanwhile, industry dynamics continue to evolve as AbbVie announced workforce reductions in its Allergan Aesthetics unit. This move reflects broader trends where companies streamline operations to prioritize core competencies and promising therapeutic areas. From a regulatory perspective, Maat Pharma's decision to seek re-examination for its graft-versus-host disease medication underscores the iterative nature of drug approval processes. Persistence in addressing regulatory feedback remains crucial as companies strive for successful market entry. In obesity management, Novo Nordisk's oral GLP-1 receptor agonist, Wegovy, gains traction as a convenient treatment option. The shift towards oral medications could significantly improve patient adherence and outcomes by offering an easier alternative to injections. Biogen's decision to terminate its collaboration with Denali Therapeutics after unsuccessful phase 2 trials for a Parkinson's disease candidate highlights the inherent risks in neurological drug development. Rigorous clinical evaluation remains essential to ensure efficacy before advancing therapies further. Despite these advancements, challenges persist as Biogen and Denali's BIIB122 failed in phase 2b trials for idiopathic Parkinson's disease. This underscores the complexity of neurological disorders and emphasizes the need for continued innovation targeting LRRK2 kinase inhibitors. In the realm of CAR-T therapies, Novartis' T-Charge platform faces competition from emerging in vivo technologies. This competitive landscape demonstrates rapid evolution within cell therapy domains, aiming to enhance efficacy and accessibility for patients. Meanwhile, strategic mergers and acquisitions continue as Liminatus Pharma acquires CAR-T biotech Innocsai for $320 million, underscoring sustained interest in oncology cell therapies. Switching gears to Eli Lilly's recent Phase 3 TRIUMPH-1 trial results for retatrutide, they reveal promising weight loss outcomes comparable to bariatric surgery. As a triple hormone receptor agonist targeting GLP-1, retatrutide holds significant potential in addressing obesity—a condition with profound public health implications. Medtronic's acquisition of SPR Therapeutics to enhance its chronic pain portfolio reflects a focus on minimally invasive treatments. Financially, Research Alliance III raised $75 million through a SPAC IPO targeting mergers with China-based biotech firms, signaling increased global collaboration within the sector. Dandelion Health's $14 million Series A funding aims to advance clinical intelligence platforms that could transform drug development through data analytics. Finally, Moderna's mRNA-based flu vaccine is set for review by the FDA's vaccine advisory committee after overcoming initial regulatory hurdles. This scrutiny highlights ongoing challenges faced by novel vaccine technologies within rigorous regulatory environments. In summary, these developments illustrate an industry at the forefront of scientific innovation while grappling with regulatory complexities and operational challenges. From antibody-drug conjugates and immunotherapy combinations to gene editing and advanced cell therapies, there's a clear commitment to improving patient outcomes through novel scientific approaches. As these trends evolve, they promise to redefine treatment landscapes across various therapeutic areas—offering new opportunities for scientific advancements and enhanced patient care worldwide.Support the show

We mark National Mental Health Awareness Month on this episode by tapping the expertise of Dr. Steve Strakowski, an internationally recognized expert in bipolar disorder, who has spent decades studying the neurobiology and treatment of mood conditions while pushing just as hard on the structural barriers that keep effective treatments out of reach for more than half the people who need them. In this conversation with Raise the Line from Elsevier host Michael Carrese, Dr. Strakowski explains why access, not science, is now the biggest obstacle to improving mental health outcomes. He also addresses the heavy toll society pays for underfunding mental health prevention and treatment programs. “The money is spent eventually, but in the most expensive places like emergency rooms and prisons, and there is the human cost of suffering and suicides." This important discussion also covers: The persistent problem of Black patients presenting with mania being misdiagnosed with schizophrenia;  Why he describes bipolar disorder as a reward-processing illness;  The emerging therapies he finds encouraging. Mentioned in this episode:Indiana University School of Medicine If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast

Wes Moore touts new wins like AstraZeneca's largest Maryland investment in a decade, Samsung Biologics' first US plant and a second Vegas Sphere coming to Prince George's County, arguing targeted incentives plus elite education can pull companies from New York and California.